

1 **Recruited macrophages that colonise the post-inflammatory peritoneal niche convert into**
2 **functionally divergent resident cells**

3 P. A. Louwe¹, L. Badiola Gomez¹, H. Webster², G. Perona-Wright², C. C. Bain¹, S. J. Forbes³, S. J.
4 Jenkins^{1*}

5

6 ¹University of Edinburgh Centre for Inflammation Research, Queens Medical Research Institute,
7 Edinburgh, EH16 4TJ, UK

8 ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, G12 8TA, UK.

9 ³Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, EH16 4UU, UK.

10

11 * Correspondence to: stephen.jenkins@ed.ac.uk

12

13

14

15

16

17

18

19 **Abstract**

20 Inflammation generally leads to substantial recruitment of monocyte-derived macrophages.
21 What regulates the fate of these cells and to what extent they can assume the identity and
22 function of resident macrophages remains unclear. We compared the normal fate of
23 inflammation-elicited macrophages in the peritoneal cavity with their potential under non-
24 inflamed conditions and in the absence of established resident macrophages. Following mild
25 inflammation, elicited macrophages persisted for at least 5 months but failed to fully assume
26 a GATA6^{hi} resident identity due to the presence of enduring resident cells. In contrast, severe
27 inflammation resulted in ablation of resident macrophages and a protracted phase wherein
28 the cavity was incapable of sustaining a resident phenotype, yet ultimately elicited cells
29 acquired a mature GATA6^{hi} identity. Elicited macrophages also exhibited divergent features
30 resulting from inflammation-driven alterations to the peritoneal cavity micro-environment
31 and environment-independent features related to origin and time-of-residency. Critically,
32 one environment-dependent feature of inflammation-elicited macrophages irrespective of
33 severity of inflammation was a failure to produce the chemokine CXCL13, which correlated
34 with a progressive loss in accumulation of peritoneal B1 cells post-inflammation. Hence,
35 rather than being predetermined, the fate of inflammation-elicited peritoneal macrophages
36 appears largely regulated by environment, changes in which result in long-term alteration in
37 function of the peritoneal macrophage compartment post-inflammation.

38

39

40 Introduction

41 Inflammation radically alters the composition and function of the tissue macrophage
42 compartment, typically leading to substantial recruitment of monocytes from the blood and
43 activation or even loss of the tissue resident cells¹. While these early cellular processes have
44 been well characterized across various tissues and models of inflammation, it remains poorly
45 understood how homeostasis within the macrophage compartment is reinstated post
46 inflammation and consequently what long-term effects inflammation may have on tissue
47 macrophage function.

48

49 In the steady-state resident macrophages across tissues share expression of core lineage-
50 related genes upon which a tissue-specific transcriptional, epigenetic and functional identity
51 is overlaid²⁻⁵. These unique molecular identities are largely established upon exposure to
52 tissue-specific environmental signals that in turn drive expression of tissue-specific
53 transcription factors. Tissue resident macrophages also have diverse developmental origins^{6,7}
54 with many tissues containing self-renewing populations largely seeded during embryogenesis
55 and short-lived bone marrow (BM)-derived populations that seemingly inhabit distinct
56 anatomical regions^{8,9}. However, in the absence of embryonically-seeded macrophages,
57 circulating monocytes appear able to give rise to long-lived and transcriptionally and
58 functionally normal resident cells¹⁰⁻¹⁴, suggesting origin may not be a key determinant of
59 macrophage identity per se, but rather tissue-specific anatomically-restricted signals and cell
60 interactions constitute a 'niche' that controls macrophage longevity and gene expression.
61 Whilst a small number of seemingly ontogeny-related transcriptional differences may
62 distinguish embryonic and monocyte-derived resident macrophages present within the same
63 'niche'^{12,14}, limited evidence suggests that even these may be gradually reprogrammed over

64 time^{13,15}. Based on these observations, it has been proposed that competition for signals that
65 drive survival of macrophages and expression of tissue-specific transcription factors dictates
66 the balance between incumbent resident macrophages and infiltrating monocytes¹⁶.

67

68 Macrophages in the peritoneal cavity regulate peritoneal B1 cells^{15,17} and provide immune
69 surveillance of the cavity¹⁸ and neighboring tissues¹⁹ but they are also implicated in many
70 pathologies, including endometriosis, post-surgical adhesions, pancreatitis and metastatic
71 cancer¹⁸. The peritoneal cavity contains two populations of resident macrophages: an
72 abundant population of so-called 'large' peritoneal macrophages (LPM) that are
73 embryonically-seeded and long-lived, and a rarer population of short-lived MHCII⁺ monocyte-
74 derived cells termed small peritoneal macrophages (SPM)²⁰. The transcriptional identity of
75 LPM is dependent upon the transcription factors GATA6^{5,21,22} and CEBP β ²³ while SPM depend
76 upon IRF4²⁴. Expression of GATA6 by LPM is driven primarily by omentum derived retinoic
77 acid at least in part via RXR α ²⁵. Despite initially having an embryonic origin, the LPM
78 population is gradually replaced by monocyte-derived cells with age, a process that occurs
79 more rapidly in males²⁰. Thus, differential rates of replenishment alters the time-of-residency
80 of each macrophage, which leads to differences in phenotype and function of LPM between
81 the sexes and with age^{15,20}. Indeed, single cell RNA-sequencing of peritoneal macrophages
82 has revealed LPM in both sexes comprise 3 transcriptionally distinct subsets that, at least in
83 females, appear to represent subsets with different times-of-residency¹⁵. However, while
84 tissue resident macrophages in solid organs are envisaged to have a static architectural niche
85 comprising stable cell interactions^{16,26} as delineated in several tissues²⁷⁻²⁹, peritoneal
86 macrophages 'float' in a fluidic environment³⁰ implying more complex interactions control
87 their maintenance, identity and sub-specialization.

88

89 Monocyte-derived macrophages recruited during inflammation typically exhibit distinct
90 transcriptional, functional and phenotypic signatures to resident cells, even in tissue sites
91 where resident cells are ordinarily replenished by monocytes^{31,32}. However, it's unclear
92 whether inflammatory macrophages are fully capable of reprogramming to become resident
93 macrophages and hence if their fate is predominantly regulated by access to appropriate
94 'niche' signals or rather predetermined during their initial differentiation. Macrophages
95 recruited to the alveolar space following influenza infection or bleomycin-induced lung
96 damage persist for many months^{33,34}, but retain significant transcriptional differences to
97 enduring resident cells. Notably, established resident macrophages exhibit a relatively poor
98 ability to engraft and reprogram upon adoptive transfer into an ectopic tissue site^{4,14},
99 suggesting that differentiation of macrophages may lead to substantial loss in plasticity.
100 Irrespective, if reprogramming of inflammatory macrophages also has an element of time-
101 dependence, their persistence would be predicted to lead to prolonged alteration in the
102 functional capacity of the tissue macrophage compartment.

103

104 In the peritoneal cavity, sterile inflammation can cause substantial contraction in number of
105 LPM through cell death or loss in fibrin clots^{30,35} but the extent of this loss appears dependent
106 on stimulus and severity of inflammation^{35,36}. While remaining LPM can subsequently
107 proliferate during the resolution phase³⁷, peritoneal inflammation^{38,39} including that caused
108 by abdominal surgery¹⁵ can lead to at least partial replacement of the long-lived LPM
109 population from the BM, with the degree of replacement seeming to correlate with the extent
110 of the preceding loss of incumbent cells³⁵. The functional implications of displacement of the
111 resident population remains unclear.

112

113 Here we studied the peritoneal cavity, a clinically relevant site commonly used to model
114 inflammatory processes, to investigate what regulates the fate of inflammatory macrophages
115 following sterile inflammation. Using adoptive transfer to unequivocally track inflammatory
116 macrophages and determine the degree to which the environment dictates the fate of these
117 cells, we demonstrate that macrophages infiltrating the cavity following mild inflammation
118 persist long-term but that competition with incumbent resident macrophages inhibits
119 effective acquisition of a mature resident phenotype. Consistent with this competition model,
120 severe inflammation, which caused ablation of incumbent resident macrophages resulted in
121 conversion of inflammatory macrophages to mature resident cells. We therefore reveal the
122 existence of a 'biochemical niche' for resident peritoneal macrophages. Competition for the
123 'niche' largely dictates the capacity of monocyte-derived cells to undergo conversion to
124 mature resident macrophages and a failure to compete retains them in a highly proliferative
125 and immunoregulatory state.

126

127

128 **Results**

129 **Inflammatory macrophages persist following mild resolving peritoneal inflammation.**

130 To investigate what regulates the fate and phenotype of inflammatory and resident
131 macrophages following resolution of sterile peritoneal inflammation, we used a well-
132 characterised model of intraperitoneal injection with low dose zymosan A (10µg/mouse), in
133 which both populations remain present following resolution of the neutrophilic phase^{36,37,40}.
134 First, to definitively delineate incumbent resident cells from inflammatory macrophages
135 recruited during the acute phase of inflammation, we utilized an established method of

136 injecting fluorescent PKH26-PCL dye intraperitoneally 24hrs before zymosan to exclusively
137 label peritoneal phagocytes present prior to inflammation³⁸. Uptake of PKH26-PCL dye was
138 largely restricted to all resident LPM and most SPM (**Supplementary Figure 1a**), identified as
139 F4/80^{Hi} or F4/80^{Lo} CD226⁺ cells respectively^{24,40}, and no free dye remained 24hrs later
140 (**Supplementary Figure 1b,c**). Subsequent injection of low-dose zymosan induced
141 disappearance of dye-labelled (Dye^{Hi}) F4/80^{Hi} resident macrophages and influx of dye-
142 negative (Dye^{Lo}) Ly6c⁺ monocytes and neutrophils within 4hrs. By day 3, neutrophils were
143 largely cleared and remaining Dye^{Lo} infiltrating cells now exhibited a predominantly F4/80^{Int}
144 Ly6c^{Lo/Int} phenotype consistent with inflammatory macrophages^{31,36} and dye^{Hi} F4/80^{Hi}
145 resident macrophages had partially recovered in number (**Figure 1a,b**), consistent with their
146 reported repopulation by self-renewal in this model³⁷. Finally, to validate our dye-based
147 tracking system, we assessed dye-labelling in tissue-protected BM chimeric mice which allow
148 recruited and resident cells to be determined definitively²⁰. This confirmed that Dye^{Lo} F4/80^{Int}
149 macrophages present in the peritoneal cavity at day 3 were derived from recruited cells as
150 evidenced by their high levels of non-host chimerism, whereas Dye^{Hi} F4/80^{Hi} cells displayed
151 low levels of chimerism, demonstrating their tissue residency (**Supplementary Figure 1d**).
152 Moreover, Dye^{Lo} F4/80^{Int} had high levels of MHCII and virtually no expression of the resident
153 macrophage marker Tim4 (**Supplementary Figure 1e**), features known to differentiate
154 inflammatory from resident macrophages during resolution^{31,36}. Thus, PKH26-PCL-labelling
155 faithfully delineated resident vs recruited macrophage subsets and importantly, this system
156 used a minimal number of surface antibodies thereby circumventing potential confounding
157 effects of adoptive transfer of antibody-coated cells.
158

159 Next, we used adoptive transfer to unequivocally determine the fate of these populations.
160 Specifically, Dye^{Hi} F4/80^{Hi} resident macrophages (RMac^{Z10}) and Dye^{Lo} F4/80^{Int} inflammatory
161 macrophages (IMac^{Z10}) were FACS-purified from C57BL/6 WT (CD45.2⁺) donor mice 3 days
162 after injection of low dose zymosan (**Figure 1a**) and transferred intraperitoneally into
163 separate congenic WT (CD45.1/2⁺) host animals. The recipient mice had been pre-treated 3
164 days prior with an equivalent dose of zymosan to ensure labelled cells were transferred into
165 a similar environment (**Figure ci**). Eight days post-transfer, transferred donor RMac^{Z10} and
166 IMac^{Z10} exhibited a similar degree of engraftment, defined as the number retrieved as a
167 proportion of those transferred, although this was somewhat greater for RMac^{Z10} (**Figure 1d**).
168 Whereas transferred RMac^{Z10} remained predominantly MHCII^{Lo}, IMac^{Z10} remained largely
169 MHCII^{Hi} and continued to express marginally less F4/80 such that the two donor populations
170 were identified with relative accuracy using these markers (**Figure 1e**). Critically, virtually all
171 transferred IMac^{Z10} expressed the LPM-specific transcription factor GATA6 but at markedly
172 lower levels than RMac^{Z10} (**Supplementary Figure 2a,b**). The host CD11b⁺ myeloid
173 compartment also contained a mixture of F4/80^{Int/Hi} MHCII^{Hi} GATA6⁺ and F4/80^{Hi} MHCII^{Lo}
174 GATA6⁺ macrophages, consistent with persistence of endogenous inflammatory and resident
175 macrophages, but also a minor fraction of GATA6⁻ F4/80^{Lo} MHCII^{Hi} cells (**Figure 1e**;
176 **Supplementary Figure 2c**) suggestive of newly generated SPM and/or CD11b⁺ DCs. Hence, by
177 combining dye-labelling and adoptive transfer, we developed a robust system to identify and
178 fate map tissue resident and inflammatory macrophages in the context of peritoneal
179 inflammation. Furthermore, our data reveal that the distinct populations of MHCII⁻ and
180 MHCII⁺ peritoneal macrophages present following zymosan-induced peritoneal
181 inflammation³⁶ arise from persistence of tissue-resident macrophages established prior to

182 inflammation and monocyte-derived macrophages recruited at the onset of inflammation,
183 respectively.

184

185 **Resident macrophages limit initial survival and phenotype of inflammatory macrophages**

186 We next explored what regulates the short-term fate of these cells. First, we transferred
187 RMac^{Z10} and IMac^{Z10} into naïve recipient mice (**Figure 1cii**) to determine whether their
188 survival and phenotype is dictated primarily by the post-inflammation micro-environment. In
189 this homeostatic environment both donor populations persisted equally (**Figure 1f**), with a
190 level of engraftment akin to that observed for RMac^{Z10} transferred to inflamed mice (**Figure**
191 **1d**). Despite this, IMac^{Z10} remained MHCII^{Hi} (**Figure 1g**) and expressed intermediate levels of
192 GATA6 (**Supplementary Figure 2d**), suggesting this phenotype was not a product of the post-
193 inflammatory micro-environment.

194

195 Next to determine if competition with resident macrophages regulates survival and
196 phenotype of IMac^{Z10}, we pre-treated recipient mice 7 days prior to transfer with clodronate-
197 loaded liposomes (**Figure 1ciii**). This regime caused rapid and prolonged loss of recipient
198 F4/80^{Hi} LPM, with the cavity being essentially devoid of these cells at the point of adoptive
199 transfer at day 7 (**Supplementary figure 2e**). In the absence of endogenous resident
200 macrophages, engraftment efficiency of IMac^{Z10} was approximately 250%, indicating these
201 cells have the ability to expand to fill the empty niche (**Figure 1h**). Furthermore, nearly 50%
202 of IMac^{Z10} adopted a more resident-like MHCII^{Lo} phenotype (**Figure 1i**) but failed to acquire
203 similar levels of GATA6 as RMac^{Z10} within this period (**Supplementary Figure 2f**). Surprisingly,
204 although RMac^{Z10} also persisted better in the depleted environment, with an engraftment
205 efficiency nearer 100%, they were unable to expand to the same degree as IMac^{Z10} (**Figure**

206 **1h).** Notably, host macrophages also repopulated the cavity during this period, yet they
207 largely exhibited an MHCII^{Hi} phenotype (**Figure 1i**) resembling that of IMac^{Z10} in their native
208 inflamed environment, suggesting these cells likely derive from Ly6C⁺ monocytes recruited to
209 the cavity post-depletion (**Supplementary Figure 2e**). We also found that irrespective of
210 environment, nearly all IMac^{Z10} expressed the GATA6-independent LPM marker CD102⁵ yet
211 few expressed Tim4 (**Supplementary Figure 2g**). Together, these data suggest that while
212 IMac^{Z10} persist through the early phases of resolution, their survival and conversion to
213 MHCII^{Lo} cells is largely regulated by the presence of competing resident macrophages.

214

215 GATA6 expression by LPM is largely induced by retinoic acid from omental and peritoneal
216 stromal cells whereas the omentum produces additional factors that can drive retinoic acid-
217 independent features of LPM^{5,41}. We therefore cultured peritoneal cells collected 11 days
218 post zyosan with all trans retinoic acid (ATRA) or omentum culture supernatant (Om factors)
219 for 24 hours to determine whether MHCII expression by inflammatory macrophages is
220 responsive to retinoic acid or other omental factors. As CD102 and Tim4 did not appear to be
221 altered in any of the *in vivo* experiments we used these to identify resident (CD102⁺/Tim4⁺)
222 and inflammatory CD102⁺Tim4⁻) macrophages post culture. Indeed, post-culture and
223 expression of these surface markers remained unchanged between treatments (**Figure 1j**).
224 Culture with ATRA led to increased expression of the GATA6 responsive marker F4/80⁵ by
225 CD102⁺/Tim4⁺ resident and CD102⁺Tim4⁻ inflammatory macrophages but not down-
226 regulation of their MHCII expression. In contrast, culture with omental supernatant led to
227 downregulation of MHCII by CD102⁺Tim4⁻ inflammatory macrophages(**Figure 1k**). Hence, the
228 presence of competing resident macrophages may limit the differentiation of inflammatory

229 macrophages to a MHCII^{Lo} resident phenotype by restricting availability of RA-independent
230 signals in the omental niche.

231

232 **Inflammatory macrophages persist long-term but retain cell-intrinsic and environment-**
233 **dependent transcriptional differences**

234 To investigate whether IMac^{Z10} can persist long-term and fully assimilate into the resident
235 LPM compartment, we continued to track these and the prevailing RMac^{Z10} following transfer
236 into native inflamed cavities versus macrophage-depleted cavities and assessed their
237 phenotype after 8 weeks. Furthermore, to understand whether inflammation changed the
238 behaviour and long-term fate of RMac^{Z10}, we included F4/80^{Hi} Dye^{Hi} LPM from naïve donors
239 (RMac) transferred into naïve mice or macrophage-depleted animals for comparison (**Figure**
240 **2a**). Notably, only 60% of the transferred RMac^{Z10} retained PKH26-PCL-labelling by this time
241 while some recipient cells had acquired dye (**Supplementary Figure 3a**) confirming the need
242 for adoptive transfer to accurately discriminate these cells. In these experiments, a similar
243 proportion of transferred IMac^{Z10} persisted in their native environment to both RMac^{Z10} and
244 RMac (**Figure 2b, left**). However, retrospective pooling of all data generated from this time-
245 point throughout our study (**Figure 2b with 4b**) revealed an overall pattern that was similar
246 to day 8, whereby IMac^{Z10} persisted marginally less well than their RMac^{Z10} counterparts
247 (**Supplementary figure 3b**). Indeed, the overall similarity in survival of donor IMac^{Z10} and
248 RMac^{Z10} between day 8 (**Figure 1d**) and week 8 (**Figure 2b**) post-transfer suggests little loss of
249 either population occurred in this time and demonstrates that macrophages elicited by an
250 inflammatory agent become long-lived resident macrophages. Furthermore, the comparable
251 survival of both IMac^{Z10} and RMac^{Z10} to RMac in naïve mice suggests that as early as day 3
252 post-zymosan injection the homeostatic mechanisms regulating longevity/autonomy of

253 peritoneal macrophages are re-instated. Following transfer into depleted recipients, IMac^{Z10}
254 again expanded significantly in number whereas RMac^{Z10} did not (**Figure 2b, right**). Likewise,
255 the similarity in persistence of engrafted IMac^{Z10} and RMac^{Z10} between day 8 (**Figure 1h**) and
256 week 8 post-transfer (**Figure 2b**) suggests that the resident peritoneal macrophage pool also
257 quickly re-establishes following depletion and resumes self-maintenance irrespective of
258 origin.

259

260 Importantly, even after 8wks in their native environment IMac^{Z10} exhibited lower expression
261 of GATA6, marginally less F4/80, and a higher proportion of MHCII⁺ cells than either RMac
262 population (**Figure 2d,e & Supplementary Figure 3d**). In contrast, prior removal of
263 competing endogenous cells through administration of clodronate liposomes allowed
264 transferred IMac^{Z10} to fully acquire the MHC^{Lo}GATA6^{Hi} phenotype of RMac^{Z10} within 8 weeks
265 (**Figure 2d,e & Supplementary Figure 3d**). To investigate the wider transcriptional
266 integration of IMac^{Z10} within the resident LPM compartment, we sorted the 3 donor
267 populations from both native and depleted environments at 8wks post-transfer and
268 investigated gene expression using the nanoString nCounter mouse myeloid panel. This
269 analysis revealed that in their native environment IMac^{Z10} remained highly transcriptionally
270 distinct from RMac^{Z10}, with 78 of the 372 detected genes being differentially expressed
271 (**Supplementary Table 1, Figure 2f, Supplementary Figure 3e**) whereas no detectable
272 differences were apparent between RMac and RMAC¹⁰(**Supplementary Table 2**). Of the 13
273 genes included in the panel considered to differentiate LPM from other tissue resident
274 macrophages^{5,41}, 11 were differentially expressed between IMac^{Z10} and RMac^{Z10}
275 (**Supplementary Figure 3f**) including *Gata6*. In contrast, *Cebpb*, which encodes the
276 transcription factor CEBP β upon which LPM are also dependent²³, was expressed equally by

277 IMac (**Supplementary Table 1**). A quarter of the genes differentially-expressed between
278 IMac^{Z10} and RMac^{Z10} overlapped with those regulated by GATA6 in LPM^{5,21,22}, including
279 *Adgre1*, which encodes F4/80, and consequently the gene signature of IMac^{Z10} largely
280 aligned with that of *Gata6*-deficient LPM^{5,21,22} (**Supplementary Figure 3g**). Furthermore,
281 comparison with our published single cell RNAseq analysis¹⁵ of LPM revealed that genes
282 expressed more highly in IMac^{Z10} overlapped exclusively with those expressed more highly
283 by LPM of recent monocyte origin in naïve female mice (e.g. *ApoE*, *Retnla*, and genes related
284 to MHCII presentation), whereas genes expressed more highly in RMac^{Z10} overlapped
285 exclusively with those expressed more highly by the most long-lived LPM (e.g. *Timd4*,
286 *Cxcl13*, and *Gata6*) (**Figure 2f**). Moreover, re-analysis of our single cell RNA-seq dataset of
287 LPM¹⁵ revealed that cluster markers that define monocyte-derived LPM overlapped
288 markedly and exclusively with genes expressed more highly by *Gata6*-deficient
289 macrophages^{5,21,22} whereas cluster markers of established LPM overlapped substantially and
290 exclusively with genes expressed more highly by *Gata6*-sufficient LPM (**Supplementary**
291 **Figure 3h**). Hence, these data suggest that differences in the degree of GATA6 expression
292 between established resident macrophages and incoming monocyte-derived macrophages
293 controls a significant proportion of the genes differentially-expressed between these
294 populations in steady-state and post-inflammation.
295
296 Critically, gene expression profiling suggested that IMac^{Z10} and RMac^{Z10} became
297 transcriptionally more similar after transfer into depleted recipients, with the number of
298 differentially expressed genes decreasing from 78 to 8 (**Figure 2f, Supplementary Table 3**).
299 Notably, differences in *Gata6* and almost all the potentially GATA6-regulated genes were lost
300 (**Supplementary Figure 3i**), as were differences in most other genes that defined clusters

301 identified in steady state¹⁵, including *Cxcl13* and MHCII-related genes. Unsurprisingly, RMac
302 and RMac^{Z10} remained transcriptionally indistinct in the macrophage-deplete environment
303 (**Supplementary Table 4**). Hence, these data suggest the majority of transcriptional
304 differences between IMac^{Z10} and RMac^{Z10} are determined by the post-inflammatory
305 environment or competition with incumbent resident macrophages for access to niche
306 signals, whereas a smaller number of differentially expressed genes may represent cell-
307 intrinsic features related to origin. Specifically, enduring resident macrophages seemingly
308 prevent IMac^{Z10} transition to a mature GATA6^{hi} phenotype, thus retaining them in a
309 transcriptional state associated with steady-state monocyte-derived LPM.

310

311 Flow-cytometric analysis confirmed that within the native post-inflammatory environment,
312 IMac^{Z10} expressed higher levels of *Sema4a*, *CD62L*, and *CCR5* and but largely failed to acquire
313 expression of *Tim4* (**Figure 2g, left**), consistent with the differential expression of *Sema4a*,
314 *Sell* (encoding for *CD62L*), *Ccr5*, and *Timd4* detected by nanoString. Similarly, IMac^{Z10} in the
315 depleted environment retained equivalently high levels of *Sema4a* and *CD62L*, and low levels
316 of *Tim4* expression (**Figure 2g, right**), consistent with these being cell-intrinsic rather than
317 environment-dependent features of IMac^{Z10} (**Figure 2f**). In line with an expression pattern
318 predominantly dictated by environmental cues, we found that IMac^{Z10} expressed more
319 variable and on the whole lower levels of *CCR5* in the macrophage-depleted environment
320 (**Figure 2g, right**). We extended this analysis to include surface markers that define newly
321 monocyte-derived (Folate receptor β (FR β)) and long-lived resident peritoneal macrophages
322 (*CD209b* and V-set immunoglobulin domain-containing 4 (*VSIG4*))¹⁵. IMac^{Z10} failed to acquire
323 equivalent expression of *CD209b* or *VSIG4* to either RMac^{Z10} population irrespective of
324 environment, whereas they exhibited comparatively high levels of FR β in the native

325 environment that, like CCR5, was lost in macrophage-depleted recipients suggesting down-
326 regulation by environmental cues (**Supplementary Figure 3j**).

327

328 Finally, we determined whether reprogramming of IMac^{Z10} may occur naturally over the
329 lifespan following inflammation. Fate-mapping for 5mths revealed continued persistence of
330 IMac^{Z10}, RMac^{Z10} and RMac transferred into their native environments (**Figure 2h**), although
331 only RMac appeared to survive as well as at 8wks (**Figure 2b**). Within this time IMac^{Z10} had
332 downregulated MHCII to levels equivalent to RMac^{Z10}, yet they continued to express lower
333 levels of GATA6 and retain higher proportions of cells expressing Sema4a, CD62L, CCR5
334 (**Figure 2i,j**) and FR β (**Supplementary Figure 3k**). Despite this, fewer IMac^{Z10} expressed CCR5
335 or FR β than at 8wks (**Figure 2g 'native' vs 2i and Supplementary Figure 3j 'native' vs 3k**),
336 consistent with gradual reprogramming of expression of these markers, whereas expression
337 of Sema4a and CD62L remained unchanged. Furthermore, IMac^{Z10} had acquired equivalent
338 levels of VSIG4 to RMac^{Z10} by this time but failed to upregulate expression of Tim4 and
339 CD209b to levels observed on the resident populations (**Figure 2i, Supplementary Figure 3k**),
340 despite the frequency of IMac^{Z10} expressing these markers increasing compared to 8wks
341 (**Figure 2i to Supplementary Figure 3k**). Of note, the low frequency of RMac and RMac^{Z10} that
342 expressed CCR5 and FR β by week 8 of transfer was seemingly reduced even further by 5mths,
343 while proportion that expressed Vsig4 and CD209b continued to rise gradually (**Figure 2g**
344 **'native' vs 2i; Supplementary Figure 3j'naïve' vs 3k**). These data are consistent with our
345 previous supposition that expression of Tim4, CD209b and VSIG4 by LPM is regulated by time-
346 of-residency and demonstrate this remains so following mild inflammation. Hence, the
347 distinct phenotype of IMac-derived LPM appear to comprise: 1) pre-determined features
348 seemingly retained over time and not reprogrammed by niche signals (CD62L, Sema4a); 2)

349 features that fail to reprogram due to an inability to compete with RMac^{Z10} for environmental
350 cues but that are reprogrammed with time (MHCII, GATA6, CCR5, FR β); and 3) features
351 related to time-of-residency irrespective of competition with RMac^{Z10} (VSIG4, Tim4, CD209b).

352

353 **Colonizing Inflammatory macrophages are functionally distinct and resemble monocyte**
354 **derived resident macrophages**

355 To determine whether colonizing inflammatory macrophages differ functionally and
356 behaviourally to established resident macrophages, we developed a gating strategy based on
357 a Tim4⁺ Sema4a⁻ (R1) and Tim4⁻ Sema4a⁺ (R3) profile to identify the majority of RMac^{Z10} and
358 IMac^{Z10}, respectively (**Figure 3a,b**). Using this approach, we were able to track the major long-
359 term changes in phenotype of the resident LPM pool triggered by inflammation without need
360 for dye-based fate-mapping (**Supplementary Figure 4b**). In addition, to determine whether
361 IMac-derived LPM are functionally similar to LPM of recent monocyte origin recruited during
362 homeostasis, we confirmed that the Tim4⁻Sema4a⁺ gate identified the majority of Tim4⁻
363 MHCII⁺ LPM in naïve mice (**Supplementary Figure 4c**), which we previously validated to
364 identify newly monocyte-derived LPM¹⁵.

365

366 Consistent with our previous observations showing that LPM of recent monocyte-origin
367 proliferate more than established LPM during homeostasis²⁰, the Sema4a⁺Tim4⁻ fraction of
368 LPM from naïve mice (subsequently referred to as **Mo-LPM** and **RM-LPM** respectively)
369 exhibited the highest level of proliferation, as determined by Ki67 expression (**Figure 3c**).
370 Similarly, Sema4a⁺ Tim4⁻ and Sema4⁻ Tim4⁺ defined-populations found 8wks post-zymosan
371 injection (subsequently referred to as **Mo^{Z10}-LPM** and **RM^{Z10}-LPM** respectively) exhibited the
372 same divergent pattern in proliferative activity (**Figure 3c**). Furthermore, while both Mo^{Z10}-

373 LPM and RM^{Z10}-LPM displayed typical macrophage morphology, the cytoplasm of RM^{Z10}-LPM
374 contained many more vacuoles (**Figure 3d**) indicative of greater phagocytic activity. Indeed,
375 both Mo^{Z10}-LPM and Mo-LPM had appreciably lower side-scatter characteristics than their
376 RM counterparts, albeit higher than SPM (**Figure 3e**). Moreover, examination of phagocytic
377 potential *in vitro* using pHrodo-labelled *Escherichia coli* particles revealed that Tim4⁺ LPM
378 from naïve mice and 8wks after inflammation were significantly more phagocytic than the
379 Tim4⁻ fraction (**Figure 3f**). Of note, incubation at 37°C for 1hr caused rapid acquisition of
380 surface Sema4a by Tim4⁺ macrophages thereby preventing analysis of Sema4a-defined
381 populations in this assay. Furthermore, re-analysis of our short-term transfer experiments
382 revealed that only Tim4⁺ recipient LPM acquired PKH26-PCL dye from donor RMac
383 irrespective of whether recipients were naïve or zymosan-injected (**Supplementary Figure**
384 **4d,e**) suggesting up-take of dying donor cells is restricted to Tim4⁺ cells. Lastly, to test
385 responsiveness to challenge, RM-LPM and Mo-LPM from naïve mice and RM^{Z10}-LPM and
386 Mo^{Z10}-LPM were purified 8wks post-zymosan injection, exposed *in vitro* to LPS and cytokine
387 and chemokine production assessed by multiplex assay. The overall response of Mo^{Z10}-LPM
388 and Mo-LPM compared to their RM counterparts was remarkably similar; both produced
389 higher levels of IL-10 and somewhat more IL-1 β and GM-CSF and less CXCL10 and TNF α .
390 (**Figure 3g,h**), suggesting these are common features of monocyte-derived LPM.
391 Furthermore, direct comparison confirmed that despite some subtle differences, Mo-LPM
392 and Mo^{Z10}-LPM produced largely similar quantities of cytokines and chemokines, as did RM-
393 LPM compared with RM^{Z10}-LPM (**Supplementary Figure 4f,g**). Hence, together with our gene
394 expression profiling, these data suggest that recency-of-monocyte origin more strongly
395 influences the behaviour of LPM than prior experience of inflammation and that persistence
396 of inflammatory macrophages leads to the expansion of a normally minor subset of IL-10

397 producing monocyte-derived LPM present under homeostatic conditions. Finally, we found
398 that purified Mo^{Z10}-LPM transferred into naïve recipient mice that subsequently received LPS
399 produced less TNF α than transferred RM^{Z10}-LPM (**Figure 3i,j**), confirming these cells also
400 respond differently to challenge *in vivo*.

401

402 **Fate of inflammatory macrophages is dependent on the severity of inflammation**

403 In the mild model of sterile peritonitis studied so far, the initial macrophage ‘disappearance
404 reaction’ and inflammatory response that occurs is relatively limited and transient³⁶. In
405 contrast, injection of a 100-fold higher dose of zymosan (1000ug/mouse) induced an almost
406 complete and protracted disappearance of F4/80^{hi} Tim4⁺ LPM concurrent with a greater and
407 more protracted influx of monocytes and neutrophils⁴² and overall increase in size of the
408 CD11b⁺ macrophage/monocyte compartment (**Supplementary Figure 5a**). Notably, the
409 CD11b⁺ population remained exclusively F4/80^{lo} MHCII^{Hi} for at least 11 days although Tim4⁺
410 cells had begun to re-emerge within this time (**Supplementary Figure 5b**). Importantly,
411 analysis in tissue-protected BM chimeric mice confirmed that the entire peritoneal
412 macrophage pool, including Tim4⁺ cells, had been replaced from the BM 3wks after high-dose
413 zymosan (**Figure 4a, Supplementary Figure 5c**). Thus, severe sterile peritoneal inflammation
414 is a physiological setting leading to the complete ablation and replacement of resident LPM.

415

416 Hence, to understand the fate of inflammatory macrophages after severe inflammation we
417 purified dye-negative inflammatory macrophages 3 days after injection of high or low-dose
418 zymosan (**IMac^{Z1000}**; **Supplementary Figure 5d**) and transferred them into their native
419 inflammatory environments. Markedly fewer donor IMac persisted at 8wks in recipients of
420 high dose zymosan compared with those receiving low dose zymosan (**Figure 4b**), consistent

421 with the greater contraction in size of the peritoneal macrophage compartment
422 **(Supplementary Figure 5a)** and the reported death of the majority of inflammation-elicited
423 macrophages that follows resolution of severe peritoneal inflammation^{31,43}. However, those
424 surviving IMac^{Z1000} in the high dose environment adopted a F4/80^{Hi}GATA6⁺ profile by 8wks
425 following severe inflammation and almost none subsequently expressed CCR5 or FR β **(Figure**
426 **4c,d,e)**. These results are consistent with a more mature phenotype, again reflecting more
427 rapid differentiation in the absence of competition from enduring resident macrophages.
428 Nevertheless, a shared deficiency of IMac-derived cells in both high and low-dose
429 environments was the failure to produce CXCL13, a GATA6^{21,22} and Rxra²⁵ independent
430 feature of LPMs. Thus, these data suggest impaired CXCL13 expression by IMac arises from
431 long-term alterations in the LPM niche that occurs irrespective of inflammation severity and
432 retinoic acid production. IMac^{Z1000} and IMac^{Z10} derived cells also largely shared the propensity
433 to express the intrinsic marker of monocyte-derived LPM Sema4a **(Figure 4e)**, and to lack
434 expression of the environment-independent but time-dependent marker VSIG4 **(Figure 4e)**.
435 More surprisingly, IMac^{Z1000} retained high levels of MHCII, and largely expressed the
436 otherwise time-dependent marker Tim4 **(Figure 4e)**. Furthermore, donor-derived
437 macrophages following severe inflammation almost perfectly resembled the phenotype of
438 host cells, consistent with their likely uniform origin from inflammatory macrophages
439 **(Supplementary Figure 5e)**. In contrast, in the lower dose environment host macrophages
440 neither aligned with RMac^{Z10} nor IMac^{Z10} but corresponded to a mixed population of these
441 cells, **(Figure 4f, Supplementary Figure 5e)** re-emphasising that phenotype is ontogeny-
442 restricted in this environment. Consequently, the LPM compartment on the whole 8 weeks
443 after high dose zymosan differed markedly to that after low dose zymosan for each marker
444 assessed **(Supplementary Figure 5e)**.

445

446 As both F4/80 and MHCII expression by IMac^{Z10} were rapidly responsive to niche signals and
447 competition with LPM after low dose zymosan (**Figure 1k, Figure 2d**), we postulated that the
448 initially prolonged absence of F4/80^{hi} LPM, rapid acquisition of Tim4 expression, and
449 persistent expression of MHCII by recruited cells (**Supplementary Figure 5b**) following severe
450 inflammation arose from an altered cavity environment. To test this, we adoptively
451 transferred 4×10^5 F4/80^{hi}, largely MHCII^{Lo}, resident macrophages from naïve mice (RMac) into
452 recipient mice 3 days after injection of high dose zymosan (**Figure 4g**). Eight days later
453 transferred cells had almost exclusively upregulated MHCII expression and markedly down-
454 regulated expression of F4/80 (**Figure 4h,i**). Moreover, transfer of RMac suppressed the rapid
455 acquisition of Tim4 by host cells, as indicated by a specific decrease in number of Tim4⁺ host
456 macrophages (**Figure 4i**). Hence, novel environmental cues following severe inflammation
457 directly drive expression of MHCII, and in conjunction with the absence of embryonically
458 seeded Tim4⁺ resident macrophages allow rapid acquisition of Tim4 by monocyte-derived
459 cells. Furthermore, there appears to be a phase of at least 11 days during severe peritonitis
460 where the cavity does not support expression of F4/80 that, given the dependence of F4/80
461 expression by LPM on GATA6 and retinoic acid^{5,21,22} (**Figure 1l**), suggests severe peritoneal
462 inflammation leads to a protracted but ultimately transient loss in retinoic acid availability.

463

464 **Inflammation leads to prolonged impairment of B1 cell accumulation in the peritoneal**
465 **cavity**

466 Although the failure to produce CXCL13 was a common feature of IMac-derived LPM (**Figure**
467 **4e**), treatment with high-dose zymosan led to a striking reduction of CXCL13⁺ peritoneal
468 macrophages (**Figure 4j**) arising from the comprehensive loss of the incumbent CXCL13-

469 expressing resident cells. Given the non-redundant role of CXCL13 in maintenance of the
470 peritoneal B1-cell pool⁴⁴, we investigated whether peritoneal inflammation led to long-term
471 disruption of B1 cells. Temporal analysis revealed that while the number of CD11b⁺ B1 cells
472 gradually increased with age under homeostatic conditions (**Figure 4k**), the degree of
473 accumulation was slightly reduced following mild inflammation and completely abrogated
474 following severe inflammation, yet neither led to absolute loss of B1 cells over baseline levels
475 (**Figure 4l**). Direct comparison of numbers of B1 cells in recipient mice from adoptive transfer
476 experiments confirmed that severe inflammation led to substantially fewer CD11b⁺
477 peritoneal B1 cells within the cavity than following mild inflammation (**Supplementary Figure**
478 **5g**). Furthermore, severe inflammation led to increased levels of serum IgM against
479 phosphorylcholine, the predominant target of natural antibodies produced by peritoneal B1
480 cells^{44,45} and to the appearance of anti-phosphorylcholine IgG (**Figure 4m**). Hence, sterile
481 peritoneal inflammation leads to a state of altered homeostasis characterized by a failure to
482 increase numbers of peritoneal CD11b⁺ B1 cells over time but which is associated with
483 increased levels and class-switching of circulating natural antibody.

484

485 **Discussion**

486 Transient peritoneal inflammation has lasting consequences for the incidence and severity of
487 future disease^{38,46} but the mechanisms underlying this effect remain largely unresolved. Here,
488 we demonstrate that inflammatory peritoneal macrophages recruited following sterile
489 inflammation persist long-term but in an aberrant state of activation largely due to an inability
490 to compete with incumbent macrophages for 'niche' signals and inflammation-driven
491 alterations in the peritoneal environment. In so doing, we reveal the existence of multiple

492 overlapping biochemical ‘niches’ that control programming of resident peritoneal
493 macrophages and which are distinct from that controlling cell survival.

494 Like Liu et al³⁵, our study suggests that the degree of replacement of LPM from the bone
495 marrow following inflammation depends on the magnitude of initial macrophage
496 disappearance. Furthermore, the increased survival of inflammatory macrophages following
497 transfer into macrophage-depleted recipients provides definitive evidence that incumbent
498 LPM impair survival of recruited cells. Hence, even without a defined physical niche,
499 monocyte contribution to resident macrophages within fluidic environments appears
500 subject to the same parameters of niche access and availability proposed by Guilliams and
501 Scott¹⁶.

502 Likewise, our data support a model whereby competition for access to a ‘biochemical’ niche
503 plays a critical role in determining the long-term transcriptional identity of inflammation-
504 elicited macrophages. Specifically, inflammation-elicited macrophages that survived
505 following mild inflammation exhibited striking long-term differences to incumbent resident
506 macrophages including high MHCII and low GATA6 expression, yet more rapidly adopted a
507 GATA-6^{hi} MHCII^{lo} resident-like phenotype and transcriptome following transfer into naive
508 macrophage-depleted mice. The failure of inflammation-elicited macrophages to down-
509 regulate MHCII expression following transfer into intact naïve mice confirms this feature
510 arises from competition with incumbent resident macrophages for signals that regulate
511 MHCII expression. Consistent with this, inflammation-elicited macrophages rapidly
512 downregulated MHCII *in vitro* in response to RA-independent omental factors. Similarly, the
513 GATA6^{lo} phenotype of inflammation-elicited macrophages following mild inflammation
514 likely arises due to competition with enduring resident macrophages for retinoic acid, since

515 more rapid acquisition of a GATA6^{hi} phenotype occurred following severe inflammation
516 concurrent with the ablation of resident macrophages. Critically, inflammation-elicited
517 macrophages gradually adopted features seemingly regulated by competition, suggesting
518 that with time these cells receive sufficient cues to acquire a mature resident phenotype.

519 Several features of inflammation-elicited macrophages appeared regulated by changes in the
520 cavity microenvironment post-inflammation. For example, severe inflammation led to
521 sustained expression of MHCII by inflammation-elicited macrophages despite natural ablation
522 of competing resident cells. Furthermore, the severely inflamed environment triggered MHCII
523 expression by adoptively transferred resident LPM that would otherwise remain largely
524 MHCII⁻ in a non-inflamed or mild inflammation setting. Hence, it seems likely severe
525 inflammation triggers release of novel signals stimulatory for MHCII.

526 A small number of genes remained differentially expressed in inflammation-elicited
527 macrophages following transfer into macrophage-depleted mice, supporting the notion that
528 developmental origin influences macrophage identity⁴⁷. These included features
529 reprogrammed over time (eg Timd4, VSIG4, Cd209b), and permanent 'legacy' features of
530 monocyte-derived cells (eg Sema4a, CD62L). The processes regulating these traits remains
531 unclear⁴⁷. However, the rapid acquisition of Tim4 expression by inflammation-elicited LPM
532 following severe inflammation and the inhibition of this by transfer of Tim4⁺ resident
533 macrophages provides proof-of-principle that seemingly origin-related time-dependent
534 features of resident macrophages can be rapidly reprogrammed by appropriate niche signals.

535 While the panel of genes assessed here was relatively limited, our findings that gene
536 expression is largely dictated by competition with resident cells or the post-inflammatory

537 environment are likely to hold true on the transcriptome as a whole. For example, the overlap
538 between environment-dependent genes and GATA-6 regulated genes^{5,21,22} suggests lower
539 GATA6 expression by inflammation-elicited macrophages controls a significant proportion of
540 their unique transcriptional profile. Similarly, the retarded expression of GATA6 by monocyte-
541 derived LPM macrophages recruited during homeostasis also likely underlies a significant
542 degree of the distinct transcriptional clustering of these cells. Critically, these data reveal that
543 GATA6 expression does not act binarily but rather the level of expression has a critical role in
544 determining LPM identity, as predicted for transcription factors with many competing target
545 sites⁴⁸.

546 One of our most intriguing findings was the difference in proliferative activity of incumbent
547 resident and inflammation-elicited LPM, with only the latter exhibiting the capacity to overtly
548 expand following transfer into macrophage-depleted mice. Notably, GATA6 directly regulates
549 proliferation of LPM²², suggesting this disparity may relate to differences in GATA6
550 expression. However, treatment with exogenous CSF1 or IL-4 stimulates recently-recruited
551 and incumbent resident macrophages to proliferate to equivalently high degrees^{20,35,49} and
552 hence, the poor expansion of incumbent resident macrophages within the macrophage-
553 deplete environment is not due to an intrinsic inability to proliferate.

554 Despite differentiating under inflamed conditions, persistent inflammation-elicited LPM bore
555 striking similarities to monocyte-derived LPM present under non-inflamed conditions. As well
556 as gene expression and proliferative activity, monocyte-derived LPM exhibited a largely
557 comparable response to LPS irrespective of condition of differentiation, most notably
558 characterized by increased production of IL-10 compared to embryonically-seeded LPM.
559 Other than IL-1 β , the profile of cytokine production by monocyte-derived LPM was the

560 opposite reported for GATA6-deficient LPM⁵⁰, suggesting other factors control their
561 differential response to LPS. Hence, mild peritonitis does not lead to the existence of a unique
562 subset of LPM but rather the expansion of a subset present in homeostasis. As we have
563 previously shown that the abundance of Tim4⁻ monocyte-derived LPM gradually increases
564 with age²⁰, it would appear that mild inflammation accelerates a process normally associated
565 with aging.

566

567 Our data also predict that inflammation-elicited LPM fail to express *Cxcl13* due to
568 inflammation-induced loss of requisite niche signals. Notably, *Cxcl13* expression by LPM is
569 sustained *in vitro* without addition of 'niche' factors⁴¹, potentially explaining why CXCL13
570 expression remains intact in incumbent LPM following mild inflammation. Hence, unlike the
571 reversible programme of gene expression controlled by GATA6 that is lost in the absence of
572 RA⁴¹, niche signals required to induce expression of CXCL13 in newly recruited macrophages
573 may not be needed to maintain expression in resident cells.

574

575 CXCL13-deficient mice are profoundly deficient in peritoneal B1 cells⁴⁴ yet CXCL13 is not
576 required for retention of B1 cells in the cavity⁵¹. We found the extent of inflammation and
577 consequently the ratio of CXCL13-producing resident macrophages to monocyte-derived
578 CXCL13⁻ LPM in the cavity correlates with a failure to accumulate peritoneal B1 cell with age.
579 As no other peritoneal lavage cells produce CXCL13^{15,44}, our data suggest CXCL13 production
580 by peritoneal macrophages is required for continued recruitment of B1 cells from the
581 circulation. Notably, replacement of peritoneal LPM by monocytes and concurrent failure to
582 expand peritoneal B1 cells also occurs following abdominal surgery¹⁵. Hence, long-term
583 dysregulation of B1 cells is likely a general feature of peritoneal inflammation. Sterile

584 peritoneal inflammation also led to elevated circulating natural antibody. Whereas splenic
585 and bone marrow B1 cells spontaneously secrete high levels of natural IgM, those in the
586 cavities do not⁵². Furthermore, levels of serum anti-PC IgM gradually drop with age⁵³. Hence,
587 we speculate that the failure to accumulate B1 cells in the peritoneal cavity may allow their
588 re-entry into tissues permissive for antibody secretion such as fat associated lymphoid
589 clusters⁵⁴.

590

591 Inflammation-driven integration of functionally distinct monocyte-derived LPM is likely to
592 occur in human peritoneal pathologies, as key features identified here are similar to published
593 work on human peritoneal macrophages. Critically, human peritoneal macrophages are also
594 considered Gata6-regulated, with 80% expressing detectable levels of this transcription factor
595 ⁵⁵. Stengel et al⁵⁶ found rapid loss of CD206⁺LPM in response to spontaneous bacterial
596 peritonitis consistent with a macrophage disappearance reaction which could allow for
597 monocyte colonization. Indeed, two subsets of peritoneal macrophages exist in peritoneal
598 ascites fluid from patients with decompensated cirrhosis, a more phagocytic subset
599 expressing high levels of VSIG4 and Tim4 and a second less phagocytic subset exhibiting low
600 levels of VSIG4, high levels of CCR2 and Sema4a, and responsiveness to retinoic acid⁵⁷.

601

602 Our study highlights how varying degrees of inflammation alter the peritoneal macrophage
603 compartment long-term and consequently reshape peritoneal homeostasis, and implicates
604 competition for niche signals, time-of-residency and alterations in niche as principal
605 determinants of these phenomena. These findings have broad importance for our
606 understanding of plasticity within the mononuclear phagocyte compartment. Furthermore,
607 understanding the consequences of inflammation in the serous cavities has major

608 implications for pathologies in which serous cavity macrophages play key roles, including
609 endometriosis⁵⁸, adhesions⁵⁹, and repair and scarring of visceral organs^{19,60} and the myriad of
610 diseases influenced by natural antibody⁶¹.

611

612

613 **Materials and Methods**

614

615 **Animals and reagents.**

616 C57BL/6 CD45.2⁺ and congenic CD45.1⁺CD45.2⁺ mice were bred and maintained in specific
617 pathogen-free facilities at the University of Edinburgh, UK. In some experiments, C57BL/6JCrI
618 mice were purchased from Charles River, UK. Mice were sex matched in all experiments and
619 used at 6-10wks of age at the start of the experiment. Experiments were permitted under
620 license by the UK Home Office and were approved by the University of Edinburgh Animal
621 Welfare and Ethical Review Body. Details of reagents can be found in **Supplementary Table**
622 **5**.

623

624 **Sterile peritoneal inflammation.**

625 To elicit sterile peritoneal inflammation, mice were injected with 10 or 1000µg of zymosan A
626 (Sigma-Aldrich) suspended in 200µl Dulbecco's PBS (Invitrogen), dPBS or left naïve as
627 indicated. In some experiments, mice were injected intraperitoneally with 250 µl of 700nm
628 PKH26-PCL in suspended in Diluent B (Sigma) 24hrs prior to zymosan. In some experiments,
629 mice were injected intraperitoneally with 0.0625mg Clodronate liposomes (Liposoma)
630 suspended in 250µl dPBS (Gibco). To elicit LPS-induced inflammation mice were injected
631 intraperitoneally with 5µg of LPS (O111:B4, Sigma-Aldrich) suspended in 200µl dPBS.

632

633 **Tissue-protected BM chimeric mice.**

634 Eight week-old female C57BL/6J CD45.1⁺CD45.2⁺ or CD45.2⁺ C57BL/6J mice were exposed to
635 a single dose of 9.5 Gy γ -irradiation under anaesthetic, with all but the hind legs of the animals
636 protected by a 2 inch lead shield. Animals were subsequently given 2-5×10⁶ BM cells from
637 female congenic CD45.2⁺ C57BL/6J or C57BL/6J CD45.1⁺CD45.2⁺ animals respectively by i.v.

638 injection and then left for 8wks, or in one experiment for 26wks due to the COVID-19-
639 pandemic, before injection of zymosan.

640

641 **Cell isolation & Flow cytometry**

642 Mice were sacrificed by exposure to rising levels of CO₂. The peritoneal cavity was lavaged
643 with a total of 9 ml wash solution (dPBS containing 2mM EDTA,1mM HEPES) or 9ml culture
644 solution (RPMI containing 1mM HEPES) if cells were used for subsequent cell culture
645 experiments. In some experiments, blood was then taken from the inferior vena cava and
646 serum isolated using Microtainer SST tubes (BD). Serum was frozen at -80°C before analysis
647 by ELISA. For chimeric mice, blood samples were also taken on the day of necropsy by cardiac
648 puncture or by cutting the carotid artery. Equal cell numbers were incubated at room
649 temperature for 10 minutes with zombie aqua viability dye (BioLegend), followed by 10-
650 minute incubation on ice with blocking buffer containing 10% mouse serum with 0.25 µg/ml
651 anti CD16/CD32 (BioLegend). Cells were incubated with indicated antibodies
652 (**Supplementary Table 5**) on ice for 30 minutes. Cells were washed with FACS buffer (2mM
653 EDTA/0.5%BSA in PBS) and if applicable stained with streptavidin conjugated or secondary
654 antibody. For intracellular staining, cells were fixed/ permeabilized using the Foxp3 staining
655 buffer (eBioscience) according to the manufacturer's protocol. For intracellular cytokine
656 staining 1E6 peritoneal cells were incubated for 4.5 hours at 37°C in 200µl sterile RPMI
657 containing Brefeldin A and Monensin (both 1:1000) in cell repellent 96 well plates (Greiner
658 Bio-One) after which cells were washed once and stained on ice for extracellular and
659 intracellular as described with one additional Fc blocking step (10 minutes on ice) after
660 fixation. Samples were acquired using FACS LSRFortessa (BD) and analysed using Flowjo
661 (Version 10.4.1,Treestar). For analysis doublets (on the basis of Forward scatter area vs
662 height) and dead cells (ZombieAqua positive) were excluded. For cell sorting, cells were
663 stained using the same protocol scaled accordingly DAPI was used as viability dye to ensure
664 real time viability detection. For adoptive transfer studies and cell culture studies cells were
665 sorted using a FACSFusion or FACS Aria sorting system with a 100µm sort nozzle. Cells sorted
666 for RNA extraction were sorted using a 70µm nozzle.

667

668 **Adoptive transfer of macrophages**

669 Cells were kept on ice at all time and all steps were carried out in a laminar flow hood using
670 sterile reagents. Cells were collected and stained as described above and where sorted using
671 flow cytometry into the indicated populations. Post sort cells where pelleted (300g, 5 min at
672 4°C), resuspended in 200µl of dPBS and counted by Casy Counter (Scharfe). For short-term
673 and long-term studies 1×10^5 and 1×10^5 cells of the indicated populations were transferred
674 respectively. For transfer of RMac^{naive} into high dose zymosan-treated recipients, 4×10^5 cells
675 were used. To study responsiveness to LPS in vivo, 2.5×10^5 cells of each of the indicated
676 populations was transferred. If required, purified populations from multiple donor mice were
677 pooled. For each experiment, purified cells were suspended in 200µl of dPBS and injected
678 intraperitoneally into recipients.

679

680 **Nanostring assay**

681 For each of the indicated donor populations 5000 cells of interest where sorted into 2µl of
682 RLT (QIAGEN). Immediately after cells where: centrifuged at maximum speed 15 seconds,
683 vortexed for 10 seconds and again centrifuged at maximum speed 15 seconds. Cells where
684 stored at -80°C until analysis using the nCounter Myeloid innate immunity panel (Nanostring)
685 according to the manufacturer's instructions. Data was analysed using the nSolver advanced
686 analysis package. Differential gene expression was determined by pairwise comparison of
687 IMAC and RMac^{naive} to RMac^{naive}. Benjamini Hochberg adjusted p-value <0.05 were
688 considered differentially expressed. Figures were generated using R packages GGplot2,
689 Pheatmap, EnhancedVolcano and GOplot.

690

691 **Gene set enrichment analysis (GSEA)**

692 Gene set of GATA6 regulated genes was obtained by analyzing GSE56711, GSE37448 and
693 GSE47049 using the GEO2R. Genes were considered GATA6 regulated if they were
694 differentially expressed ($p < 0.05$) in 2 out of 3 published GATA6^{KO} datasets^{5,21,22}. The gene list
695 was split into GATA6^{KO} up and downregulated gene sets. GSEA was carried out using GSEA
696 desktop 4.1 (Broad Institute). RNA levels of genes in RMac^{Z10} and IMac^{Z10} were analyzed
697 using default settings and 10.000 geneset permutations.

698

699 **Omentum factors production and treatment**

700 Omentum factors were generated by culturing the omentum from naïve mice in 1ml of
701 macrophage serum free media (GIBCO) for 5 days as described⁵ after which medium was
702 collected, centrifuged at 300g and the supernatant collected and diluted in 1:2 in media.
703 Peritoneal cells were collected 11 days post low dose zymosan were collected as described
704 under sterile conditions and 5×10^5 plated and incubated for 2 hours at 37°C in cell culture
705 medium (RPMI, 10%FCS, 1% L-Glutamine and 1% Pen/strep supplemented with 20ng/ml
706 CSF1) after which medium was aspirated and cells were incubated in 250µl cell culture
707 medium with 250µl Omentum factors or macrophage serum free media with ATRA (Sigma,
708 1µm) or without for 24 hours. Then, medium was removed and plate was incubated with
709 5mM EDTA in ice cold PBS for 10 minutes on ice to collect cells. Wells were repeatedly washed
710 with ice cold 5mM EDTA PBS and wells were inspected using a microscope to confirm
711 negligible adherent cells remained. Cells were quantified and prepared for flow cytometry as
712 described.

713

714 **Cytokine production assay**

715 Cells were kept on ice at all time and all steps were carried out using sterile reagents in a
716 laminar flow hood using the sort protocol described. For each population of interest 1×10^3
717 cells per condition were sorted into 75µl sort medium (Folic acid deficient RPMI containing
718 20% FCS (Low endotoxin), 2% L-Glutamine and 2% Pen/strep). Cells were centrifuged at 100g
719 at 4 degrees for 5 minutes. The total mixture was then transferred into a 96 well plate
720 incubated at 37°C for 2 hours. Media was gently aspirated and cells were resuspended in 75µl
721 cell culture medium (Folic acid deficient RPMI supplemented with 1µg/ml Folic Acid (Sigma-
722 Aldrich), 10% FCS (Low endotoxin), 1% L-glutamine and 1% Pen/Strep). Where indicated cells
723 received a final concentration of LPS of 1ng/ml (O11:B4, Sigma-Aldrich) in cell culture
724 medium or equivalent amount of dPBS. Cells were incubated for 14 hours and supernatant
725 was collected and analysed for cytokine release using the Legendplex Mouse Anti-Virus or
726 Mouse Inflammation panel according to the manufacturers protocol. Data was acquired using
727 an Attune flow cytometer and analysed using the Legendplex analysis software.

728

729 **Phrodo phagocytosis assay**

730 Cells were collected and 2×10^6 cells/sample were stained as described. Each sample was
731 washed twice with ice cold RPMI and was split into two tubes each and left on ice for 10
732 minutes. Then to each tube $10 \mu\text{l}$ of Phrodo E.Coli particles was added and for each sample
733 one tube was incubated at 37°C and one at 4°C for 1hr. All samples were placed on ice and
734 washed once using $300 \mu\text{l}$ Buffer C and were then resuspended in $300 \mu\text{l}$ Buffer C. Cells were
735 analysed directly after finishing the protocol. Data is presented as normalized Phrodo mean
736 fluorescence intensity (MFI 37°C - MFI 4°C).

737

738

739 ***Enzyme-Linked Immunosorbant assay's***

740 96-well flat-bottom high-binding polystyrene plates (Corning) were coated with $50 \mu\text{l}$ of
741 $2 \mu\text{g/ml}$ phosphorylcholine conjugated to BSA (PC-BSA; 2B Scientific) diluted in PBS at 4°C
742 overnight. Plates were then blocked with $100 \mu\text{l}$ of blocking buffer (1% Casein in PBS; VWR)
743 for 1.5hr at room temperature, before serum samples were added at 1:100 dilution in $50 \mu\text{l}$
744 blocking buffer and incubated for 2hr at room temperature. Wells without antigen were used
745 as blank controls for each sample to measure non-specific antibody binding. Plates were then
746 incubated with 1:5000 HRP-conjugated anti-mouse IgG (Abcam) or 1:2000 anti-mouse IgM
747 (Southern Biotech) in blocking buffer for 1h at room temperature before addition of TMB
748 (Seracare). After 10 minutes the reaction was stopped with 0.16M sulphuric acid solution and
749 the OD_{450} value measured. Values for blank controls were then subtracted for each sample to
750 quantify antigen-specific antibody levels. Plates were washed twice with 0.1% Tween20
751 (Sigma-Aldrich) in PBS between all steps except before addition of TMB, when they were
752 washed 5 times.

753

754 ***Statistics.*** Statistics were performed using Prism 7 (GraphPad Software). The statistical test
755 used in each experiment is detailed in the relevant figure legend.

756

757 ***Accession codes.*** Nanostring gene expression data that support the findings of this study have
758 been deposited in -----

759

760 ***Data availability.*** Data that support the findings of this study are available from the

761 corresponding authors upon reasonable request.

762

763 **Acknowledgements**

764 Flow cytometry data were generated with support from the QMRI Flow Cytometry and Cell
765 Sorting Facility, University of Edinburgh. Nanostring was performed by the Host and Tumour
766 Profiling Unit Services Facility, MRC Institute for Genetics and Molecular Medicine, University
767 of Edinburgh. We thank Dr Mohini Gray for kind provision of PC-BSA and Prof Judith Allen for
768 comments on the manuscript.

769

770 This work was funded by a Wellcome Trust PhD studentship to P.A.L (203909/Z/16/A) with
771 additional support from the Medical Research Council UK (MR/L008076/1 to S.J.J).

772

773

774 **Author Contributions**

775 P.A.L. designed and performed most experiments, analysed and interpreted the data, and
776 wrote the manuscript. L.B.G. performed and analysed antibody ELISA's. H.W and G.P-W.
777 performed experiments. C.C.B contributed to design of experiments and interpretation of
778 data. S.J.F. provided critical feedback on the study design. S.J.J. conceived, designed and
779 performed experiments, analysed and interpreted the data, wrote the manuscript, and
780 supervised the project.

781

782 **Competing financial interests**

783 The authors declare no competing financial interests

784 References


- 785 1 Davies, L. C., Jenkins, S. J., Allen, J. E. & Taylor, P. R. Tissue-resident macrophages.
786 *Nature immunology* **14**, 986-995, doi:10.1038/ni.2705 (2013).
- 787 2 Gautier, E. L. *et al.* Gene-expression profiles and transcriptional regulatory pathways
788 that underlie the identity and diversity of mouse tissue macrophages. *Nature*
789 *immunology* **13**, 1118-1128, doi:10.1038/ni.2419 (2012).
- 790 3 Gosselin, D. *et al.* Environment drives selection and function of enhancers controlling
791 tissue-specific macrophage identities. *Cell* **159**, 1327-1340,
792 doi:10.1016/j.cell.2014.11.023 (2014).
- 793 4 Lavin, Y. *et al.* Tissue-resident macrophage enhancer landscapes are shaped by the
794 local microenvironment. *Cell* **159**, 1312-1326, doi:10.1016/j.cell.2014.11.018 (2014).
- 795 5 Okabe, Y. & Medzhitov, R. Tissue-specific signals control reversible program of
796 localization and functional polarization of macrophages. *Cell* **157**, 832-844,
797 doi:10.1016/j.cell.2014.04.016 (2014).
- 798 6 Ginhoux, F. & Guilliams, M. Tissue-Resident Macrophage Ontogeny and Homeostasis.
799 *Immunity* **44**, 439-449, doi:10.1016/j.immuni.2016.02.024 (2016).
- 800 7 Hashimoto, D. *et al.* Tissue-resident macrophages self-maintain locally throughout
801 adult life with minimal contribution from circulating monocytes. *Immunity* **38**, 792-
802 804, doi:10.1016/j.immuni.2013.04.004 (2013).
- 803 8 De Schepper, S. *et al.* Self-Maintaining Gut Macrophages Are Essential for Intestinal
804 Homeostasis. *Cell* **175**, 400-415 e413, doi:10.1016/j.cell.2018.07.048 (2018).
- 805 9 Siero, F. *et al.* A Liver Capsular Network of Monocyte-Derived Macrophages Restricts
806 Hepatic Dissemination of Intraperitoneal Bacteria by Neutrophil Recruitment.
807 *Immunity* **47**, 374-388 e376, doi:10.1016/j.immuni.2017.07.018 (2017).
- 808 10 Beattie, L. *et al.* Bone marrow-derived and resident liver macrophages display unique
809 transcriptomic signatures but similar biological functions. *J Hepatol* **65**, 758-768,
810 doi:10.1016/j.jhep.2016.05.037 (2016).
- 811 11 David, B. A. *et al.* Combination of Mass Cytometry and Imaging Analysis Reveals Origin,
812 Location, and Functional Repopulation of Liver Myeloid Cells in Mice.
813 *Gastroenterology* **151**, 1176-1191, doi:10.1053/j.gastro.2016.08.024 (2016).
- 814 12 Gibbings, S. L. *et al.* Transcriptome analysis highlights the conserved difference
815 between embryonic and postnatal-derived alveolar macrophages. *Blood* **126**, 1357-
816 1366, doi:10.1182/blood-2015-01-624809 (2015).
- 817 13 Scott, C. L. *et al.* Bone marrow-derived monocytes give rise to self-renewing and fully
818 differentiated Kupffer cells. *Nat Commun* **7**, 10321, doi:10.1038/ncomms10321
819 (2016).
- 820 14 van de Laar, L. *et al.* Yolk Sac Macrophages, Fetal Liver, and Adult Monocytes Can
821 Colonize an Empty Niche and Develop into Functional Tissue-Resident Macrophages.
822 *Immunity* **44**, 755-768, doi:10.1016/j.immuni.2016.02.017 (2016).
- 823 15 Bain, C. C. *et al.* Rate of replenishment and microenvironment contribute to the
824 sexually dimorphic phenotype and function of peritoneal macrophages. *Sci Immunol*
825 **5**, doi:10.1126/sciimmunol.abc4466 (2020).
- 826 16 Guilliams, M. & Scott, C. L. Does niche competition determine the origin of tissue-
827 resident macrophages? *Nature reviews. Immunology* **17**, 451-460,
828 doi:10.1038/nri.2017.42 (2017).

- 829 17 Zeng, Z. *et al.* Sex-hormone-driven innate antibodies protect females and infants
830 against EPEC infection. *Nature immunology* **19**, 1100-1111, doi:10.1038/s41590-018-
831 0211-2 (2018).
- 832 18 Bain, C. C. & Jenkins, S. J. The biology of serous cavity macrophages. *Cellular*
833 *immunology*, doi:10.1016/j.cellimm.2018.01.003 (2018).
- 834 19 Wang, J. & Kubes, P. A Reservoir of Mature Cavity Macrophages that Can Rapidly
835 Invade Visceral Organs to Affect Tissue Repair. *Cell* **165**, 668-678,
836 doi:10.1016/j.cell.2016.03.009 (2016).
- 837 20 Bain, C. C. *et al.* Long-lived self-renewing bone marrow-derived macrophages displace
838 embryo-derived cells to inhabit adult serous cavities. *Nat Commun* **7**, ncomms11852,
839 doi:10.1038/ncomms11852 (2016).
- 840 21 Gautier, E. L. *et al.* Gata6 regulates aspartoacylase expression in resident peritoneal
841 macrophages and controls their survival. *The Journal of experimental medicine* **211**,
842 1525-1531, doi:10.1084/jem.20140570 (2014).
- 843 22 Rosas, M. *et al.* The transcription factor Gata6 links tissue macrophage phenotype and
844 proliferative renewal. *Science* **344**, 645-648, doi:10.1126/science.1251414 (2014).
- 845 23 Cain, D. W. *et al.* Identification of a tissue-specific, C/EBPbeta-dependent pathway of
846 differentiation for murine peritoneal macrophages. *J Immunol* **191**, 4665-4675,
847 doi:10.4049/jimmunol.1300581 (2013).
- 848 24 Kim, K. W. *et al.* MHC II+ resident peritoneal and pleural macrophages rely on IRF4 for
849 development from circulating monocytes. *The Journal of experimental medicine* **213**,
850 1951-1959, doi:10.1084/jem.20160486 (2016).
- 851 25 Casanova-Acebes, M. *et al.* RXRs control serous macrophage neonatal expansion and
852 identity and contribute to ovarian cancer progression. *Nat Commun* **11**, 1655,
853 doi:10.1038/s41467-020-15371-0 (2020).
- 854 26 Zhou, X. *et al.* Circuit Design Features of a Stable Two-Cell System. *Cell* **172**, 744-757
855 e717, doi:10.1016/j.cell.2018.01.015 (2018).
- 856 27 Bonnardel, J. *et al.* Stellate Cells, Hepatocytes, and Endothelial Cells Imprint the
857 Kupffer Cell Identity on Monocytes Colonizing the Liver Macrophage Niche. *Immunity*
858 **51**, 638-654 e639, doi:10.1016/j.immuni.2019.08.017 (2019).
- 859 28 Chakarov, S. *et al.* Two distinct interstitial macrophage populations coexist across
860 tissues in specific subtissular niches. *Science* **363**, doi:10.1126/science.aau0964
861 (2019).
- 862 29 Mondor, I. *et al.* Lymphatic Endothelial Cells Are Essential Components of the
863 Subcapsular Sinus Macrophage Niche. *Immunity* **50**, 1453-1466 e1454,
864 doi:10.1016/j.immuni.2019.04.002 (2019).
- 865 30 Zhang, N. *et al.* Expression of factor V by resident macrophages boosts host defense
866 in the peritoneal cavity. *The Journal of experimental medicine* **216**, 1291-1300,
867 doi:10.1084/jem.20182024 (2019).
- 868 31 Gautier, E. L., Ivanov, S., Lesnik, P. & Randolph, G. J. Local apoptosis mediates
869 clearance of macrophages from resolving inflammation in mice. *Blood* **122**, 2714-
870 2722, doi:10.1182/blood-2013-01-478206 (2013).
- 871 32 Zigmond, E. *et al.* Ly6C hi monocytes in the inflamed colon give rise to
872 proinflammatory effector cells and migratory antigen-presenting cells. *Immunity* **37**,
873 1076-1090, doi:10.1016/j.immuni.2012.08.026 (2012).

- 874 33 Aegerter, H. *et al.* Influenza-induced monocyte-derived alveolar macrophages confer
875 prolonged antibacterial protection. *Nature immunology* **21**, 145-157,
876 doi:10.1038/s41590-019-0568-x (2020).
- 877 34 Misharin, A. V. *et al.* Monocyte-derived alveolar macrophages drive lung fibrosis and
878 persist in the lung over the life span. *The Journal of experimental medicine* **214**, 2387-
879 2404, doi:10.1084/jem.20162152 (2017).
- 880 35 Liu, Z. *et al.* Fate Mapping via Ms4a3-Expression History Traces Monocyte-Derived
881 Cells. *Cell* **178**, 1509-1525 e1519, doi:10.1016/j.cell.2019.08.009 (2019).
- 882 36 Davies, L. C. *et al.* Distinct bone marrow-derived and tissue-resident macrophage
883 lineages proliferate at key stages during inflammation. *Nat Commun* **4**, 1886,
884 doi:10.1038/ncomms2877 (2013).
- 885 37 Davies, L. C. *et al.* A quantifiable proliferative burst of tissue macrophages restores
886 homeostatic macrophage populations after acute inflammation. *European journal of*
887 *immunology* **41**, 2155-2164, doi:10.1002/eji.201141817 (2011).
- 888 38 Newson, J. *et al.* Resolution of acute inflammation bridges the gap between innate
889 and adaptive immunity. *Blood* **124**, 1748-1764, doi:10.1182/blood-2014-03-562710
890 (2014).
- 891 39 Yona, S. *et al.* Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue
892 Macrophages under Homeostasis. *Immunity* **38**, 79-91,
893 doi:10.1016/j.immuni.2012.12.001 (2013).
- 894 40 Liao, C. T. *et al.* IL-10 differentially controls the infiltration of inflammatory
895 macrophages and antigen-presenting cells during inflammation. *European journal of*
896 *immunology* **46**, 2222-2232, doi:10.1002/eji.201646528 (2016).
- 897 41 Buechler, M. B. *et al.* A Stromal Niche Defined by Expression of the Transcription
898 Factor WT1 Mediates Programming and Homeostasis of Cavity-Resident
899 Macrophages. *Immunity* **51**, 119-130 e115, doi:10.1016/j.immuni.2019.05.010 (2019).
- 900 42 Cash, J. L., White, G. E. & Greaves, D. R. Chapter 17. Zymosan-induced peritonitis as a
901 simple experimental system for the study of inflammation. *Methods Enzymol* **461**,
902 379-396, doi:10.1016/S0076-6879(09)05417-2 (2009).
- 903 43 Gundra, U. M. *et al.* Vitamin A mediates conversion of monocyte-derived
904 macrophages into tissue-resident macrophages during alternative activation. *Nature*
905 *immunology* **18**, 642-653, doi:10.1038/ni.3734 (2017).
- 906 44 Ansel, K. M., Harris, R. B. & Cyster, J. G. CXCL13 is required for B1 cell homing, natural
907 antibody production, and body cavity immunity. *Immunity* **16**, 67-76 (2002).
- 908 45 Masmoudi, H., Mota-Santos, T., Huetz, F., Coutinho, A. & Cazenave, P. A. All T15 Id-
909 positive antibodies (but not the majority of VHT15+ antibodies) are produced by
910 peritoneal CD5+ B lymphocytes. *Int Immunol* **2**, 515-520, doi:10.1093/intimm/2.6.515
911 (1990).
- 912 46 Newson, J. *et al.* Inflammatory Resolution Triggers a Prolonged Phase of Immune
913 Suppression through COX-1/mPGES-1-Derived Prostaglandin E2. *Cell Rep* **20**, 3162-
914 3175, doi:10.1016/j.celrep.2017.08.098 (2017).
- 915 47 Bleriot, C., Chakarov, S. & Ginhoux, F. Determinants of Resident Tissue Macrophage
916 Identity and Function. *Immunity* **52**, 957-970, doi:10.1016/j.immuni.2020.05.014
917 (2020).
- 918 48 Brewster, R. C. *et al.* The transcription factor titration effect dictates level of gene
919 expression. *Cell* **156**, 1312-1323, doi:10.1016/j.cell.2014.02.022 (2014).

- 920 49 Jenkins, S. J. *et al.* Local macrophage proliferation, rather than recruitment from the
921 blood, is a signature of TH2 inflammation. *Science* **332**, 1284-1288,
922 doi:10.1126/science.1204351 (2011).
- 923 50 Ipseiz, N. *et al.* Tissue-resident macrophages actively suppress IL-1beta release via a
924 reactive prostanoid/IL-10 pathway. *The EMBO journal* **39**, e103454,
925 doi:10.15252/embj.2019103454 (2020).
- 926 51 Ha, S. A. *et al.* Regulation of B1 cell migration by signals through Toll-like receptors.
927 *The Journal of experimental medicine* **203**, 2541-2550, doi:10.1084/jem.20061041
928 (2006).
- 929 52 Choi, Y. S., Dieter, J. A., Rothausler, K., Luo, Z. & Baumgarth, N. B-1 cells in the bone
930 marrow are a significant source of natural IgM. *European journal of immunology* **42**,
931 120-129, doi:10.1002/eji.201141890 (2012).
- 932 53 Holodick, N. E., Vizconde, T., Hopkins, T. J. & Rothstein, T. L. Age-Related Decline in
933 Natural IgM Function: Diversification and Selection of the B-1a Cell Pool with Age. *J*
934 *Immunol* **196**, 4348-4357, doi:10.4049/jimmunol.1600073 (2016).
- 935 54 Jackson-Jones, L. H. *et al.* Fat-associated lymphoid clusters control local IgM secretion
936 during pleural infection and lung inflammation. *Nat Commun* **7**, 12651,
937 doi:10.1038/ncomms12651 (2016).
- 938 55 Ruiz-Alcaraz, A. J. *et al.* Characterization of human peritoneal monocyte/macrophage
939 subsets in homeostasis: Phenotype, GATA6, phagocytic/oxidative activities and
940 cytokines expression. *Sci Rep* **8**, 12794, doi:10.1038/s41598-018-30787-x (2018).
- 941 56 Stengel, S. *et al.* Peritoneal Level of CD206 Associates With Mortality and an
942 Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and
943 Spontaneous Bacterial Peritonitis. *Gastroenterology* **158**, 1745-1761,
944 doi:10.1053/j.gastro.2020.01.029 (2020).
- 945 57 Irvine, K. M. *et al.* CR1g-expressing peritoneal macrophages are associated with
946 disease severity in patients with cirrhosis and ascites. *JCI Insight* **1**, e86914,
947 doi:10.1172/jci.insight.86914 (2016).
- 948 58 Hogg, C. D., P.; Rosser, M.; Mack, M.; Soong, D.; Pollard, J.W.; Jenkins, S.J.; Horne,
949 A.W.; Greaves, E. Macrophages inhibit and enhance endometriosis depending on their
950 origin. *bioRxiv* <https://doi.org/10.1101/2020.04.30.070003> (2020).
- 951 59 Honjo, K. *et al.* Plasminogen activator inhibitor-1 regulates macrophage-dependent
952 postoperative adhesion by enhancing EGF-HER1 signaling in mice. *FASEB journal :*
953 *official publication of the Federation of American Societies for Experimental Biology*
954 **31**, 2625-2637, doi:10.1096/fj.201600871RR (2017).
- 955 60 Deniset, J. F. *et al.* Gata6(+) Pericardial Cavity Macrophages Relocate to the Injured
956 Heart and Prevent Cardiac Fibrosis. *Immunity* **51**, 131-140 e135,
957 doi:10.1016/j.immuni.2019.06.010 (2019).
- 958 61 Hernandez, A. M. & Holodick, N. E. Editorial: Natural Antibodies in Health and Disease.
959 *Front Immunol* **8**, 1795, doi:10.3389/fimmu.2017.01795 (2017).
- 960

Figure 1



962
963

964

965 **Figure 1. Competition mediates inflammatory macrophage phenotype early post resolution**

966 **(a)** Representative expression of F4/80, Ly6C and PKH26-PCL labelling and identification of F4/80^{HI}
967 PKH26-PCL^{HI} resident macrophages, PKH26-PCL^{LO} Ly6c⁺ monocytes and PKh26-PCL^{LO} F4/80^{INT}
968 inflammatory macrophages in the naïve peritoneal cavity, 4hrs and 3d post 10µg zymosan.


- 969 **(b)** Absolute numbers of RMac, Monocytes, IMac and Neutrophils the naïve peritoneal cavity (n=8),
970 4hrs post zymosan (n=9) and 3d post zymosan (n=9). * $p < 0.05$, **** $p < 0.0001$ determined by one-way
971 ANOVA with Tukey's multiple comparisons test.
- 972 **(c)** Experimental scheme for the adoptive transfer of RMac^{Z10} (blue) or IMac^{Z10} (orange) sourced from
973 CD45.2 mice 3d after injection of 10 μ g zymosan into mirroring inflamed (i), naïve (ii) or
974 macrophage-depleted (iii) CD45.1/2 recipient mice.
- 975 **(d)** Engraftment efficiency of transferred RMac^{Z10} (n=6) and IMac^{Z10} (n=8) 8d after transfer into
976 mirroring inflamed recipients. * $p < 0.05$ determined by Mann-Whitney test.
- 977 **(e)** Expression of F4/80 and MHCII by donor RMac^{Z10} (n=6), IMac^{Z10} (n=8) or host (n=14) cells 8d
978 post transfer. **** $p < 0.0001$ determined by two-way ANOVA and post hoc Tukey test
- 979 **(f)** Engraftment efficiency of transferred RMac^{Z10} (n=7) and IMac^{Z10} (n=7) 8d after transfer into naïve
980 recipients.
- 981 **(g)** Expression of F4/80 and MHCII by donor RMac^{Z10} (n=7), IMac^{Z10} (n=7) or host (n=14) cells 8d
982 after transfer. **** $p < 0.0001$ determined by two-way ANOVA and post hoc Tukey test
- 983 **(h)** Engraftment efficiency of transferred RMac^{Z10} (n=8) and IMac^{Z10} (n=6) 8d after transfer into
984 clodronate depleted recipients. * $p < 0.05$ determined by Mann-Whitney test.
- 985 **(i)** Expression of F4/80 and MHCII by donor RMac^{Z10} (n=8), IMac^{Z10} (n=6) or host (n=14) cells 8d
986 after transfer. **** $p < 0.0001$ determined by two-way ANOVA and post hoc Tukey test
- 987 **(j)** Representative expression of CD102 and Tim4 by cultured cells after 24hrs culture with indicated
988 treatment.
- 989 **(k)** Proportion of macrophage subsets that express MHCII and F4/80 MFI after 24hrs culture with
990 indicated treatment. ** $p < 0.01$ determined by one way Anova and Dunnet's multiple comparisons test
991 for each subset individually, followed by Bonferroni adjustment.

992

993 For all experiments, data are presented as mean \pm standard deviation with each symbol representing
994 an individual animal, except for (l) where symbols represent individual culture wells. All data were
995 pooled from 3 independent experiments except for (k,l), which were pooled from 2 experiments.
996 Where presented, host cells represented by squares or circles are from animals given RMac^{Z10} or
997 IMac^{Z10} respectively.

998

Figure 2



999

1000

1001

1002 **Figure 2 Colonizing inflammatory macrophages are long lived but retain intrinsic and**
 1003 **environment-dependent differences to RMac.**

1004 **(a)** Experimental scheme for the adoptive transfer of RMac from naïve mice or RMac^{Z10} and

1005 IMac^{Z10} obtained 3d after injection of 10µg zymosan into mirroring naïve, inflamed or clodronate

1006 depleted recipients.

1007 **(b)** Engraftment efficiency of transferred RMac, RMac^{Z10} and IMac^{Z10} 8wk after transfer into the
1008 mirroring recipients (left; n=13, n=9, n=9) or depleted recipients (right; n=10, n=10, n=8) **p<0.01
1009 determined by one-way ANOVA and Tukey's multiple comparisons test

1010 **(c)** Representative expression of F4/80 and MHCII of indicated donor populations 8wk after transfer
1011 into native (left) or clodronate depleted (right) recipients. Bottom, representative expression of host
1012 myeloid cells post zymosan or post depletion.

1013 **(d)** Proportion of donor RMac, RMac^{Z10} and IMac^{Z10} that express MHCII 8wk after transfer into
1014 mirroring recipients (left; n=13,11,11) or depleted recipients (right; 10, 10, 8). **p<0.01 determined
1015 by one-way ANOVA and Tukey's multiple comparisons test

1016 **(e)** Mean fluorescence intensity of GATA6 after transfer of RMac, RMac^{Z10} or IMac^{Z10} 8wk after into
1017 native (left; n=12,11,11) or depleted (right; n=10,10,8) recipients. ****p<0.0001 determined by one-
1018 way ANOVA and Tukey's multiple comparisons test

1019 **(f)** Venn diagram indicating overlap between genes differentially (adj p value <0.05) expressed
1020 between RMac^{Z10} and IMac^{Z10} 8wk after transfer into the native (blue) or depleted (red) environment.
1021 Below, circus plot depicting fold change of differentially expressed genes (left side) that are cluster
1022 markers for single cell clusters (right side) identified by Bain et al¹⁵.

1023 **(g)** Expression of markers of interest by CD102⁺ RMac (black), RMac^{Z10} (blue) and IMac^{Z10} (orange)
1024 8wk after transfer into mirroring (left; n=7,6,6) or depleted recipients (right; n= 5, 5, 4). **p<0.01,
1025 **p<0.01 ***p<0.001 determined by one way ANOVA and Dunnet's multiple comparisons test for
1026 each marker individually, followed by Bonferroni adjustment.

1027 **(h)** Engraftment efficiency of transferred RMac, RMac^{Z10} and IMac^{Z10} 22wks after transfer into the
1028 mirroring recipients (n=4, 5, 5). *p<0.05 determined by one-way ANOVA and Tukey's multiple
1029 comparisons test

1030 **(i)** Expression of markers of interest by CD102⁺ RMac (black), RMac^{Z10} (blue) and IMac^{Z10} (orange)
1031 22wks after transfer into mirroring (n=4, 5, 5) recipients. **p<0.01 ***p<0.001 determined by one
1032 way ANOVA and Dunnet's multiple comparisons test for each marker individually, followed by
1033 Bonferroni adjustment.


1034 **(j)** Mean fluorescence intensity of GATA6, 22wks after transfer of RMac, RMac^{Z10} or IMac^{Z10} into
1035 native (n=4, 5, 5) recipients. *p<0.05 determined by one-way ANOVA and Tukey's multiple
1036 comparisons test

1037

1038 For all experiments, data are presented as mean ± standard deviation with each symbol representing
1039 an individual animal. All data were pooled from at least 2 independent experiments, except for **(j)**
1040 which is a single representative experiment. Where presented, host cells represented by squares or
1041 circles are from animals given RMac^{Z10} or IMac^{Z10} respectively.

1042

Figure 3



1043

1044

1045

1046

1047 **Figure 3. Monocyte derived LPM are functionally distinct from embryonically seeded LPM**

1048 **(a)** Representative expression of Tim4 and Sema4a by donor RMac, RMac^{Z10} and IMac^{Z10} 8wks post

1049 transfer and their respective hosts (bottom)

1050 **(b)** Proportion of donor RMac^{Z10} (blue circle, n=6), IMac^{Z10} (orange circle, n=6) and their respective

1051 host (grey) macrophages with Sema4a^{LO}Tim4⁺ (R1), Sema4a^{HI}Tim4⁺ (R2), Sema4a^{HI}Tim4⁻ (R3) or

1052 Sema4a^{Lo}Tim4⁻ (R4) phenotype. . ***p<0.001, ****p<0.0001 determined by one way ANOVA and
1053 Tukey's multiple comparisons test

1054 (c) Expression of Ki67 by naïve RM-LPM and Mo-LPM (n=5) or 8wk post zymosan RM^{Z10}-LPM and
1055 Mo^{Z10}-LPM (n=8). *p<0.05, **p<0.01 ****p<0.0001 determined by one way ANOVA and Tukey's
1056 multiple comparisons test

1057 (d) Morphological appearance of RM^{Z10}-LPM and Mo^{Z10}-LPM purified 8wks post zymosan.

1058 (e) Mean side scatter of naïve RM-LPM, Mo-LPM, SPM (n=5) or 8wks post zymosan RM^{Z10}-LPM ,
1059 Mo^{Z10}-LPM and SPM^{Z10}(n=8). **p<0.01, ***p<0.001 ****p<0.0001 determined by one way ANOVA
1060 and Tukey's multiple comparisons test

1061 (f) Uptake of Phrodo E.coli particles by naïve (n=6) or 8wks post zymosan (n=9) Tim4⁺ and Tim4⁻
1062 macrophages shown as normalized Phorodo mean fluorescence intensity (MFI 37°C- MFI 4°C).
1063 **p<0.01, ***p<0.001 determined by paired student's t test.

1064 (g) Secreted cytokine/chemokine profile collected from cultures of RM-LPM (n=6, teal) or Mo-LPM
1065 (n=5, red) sourced from naïve animals 14hrs after culture with LPS (1ng/ml). Results are shown as
1066 log2 fold change in mean pg/ml over the mean RM-LPM using a box-and-whiskers plot.
1067 **p<0.001***p<0.0001 determined by repeated student's t test with Holm-Sidak correction.

1068 (h) Secreted cytokine/chemokine profile collected from cultures of RM^{Z10}-LPM (n=8, teal) or Mo^{Z10}-
1069 LPM (n=8, red) sourced 8wks post zymosan, 14hrs after culture with LPS (1ng/ml). Results are
1070 shown as log2 fold change in mean pg/ml over the mean RM^{Z10}-LPM using a box-and-whiskers plot.
1071 **p<0.001***p<0.0001 determined by repeated student's t test with Holm-Sidak correction.

1072 (i) Experimental scheme for the adoptive transfer of RM^{Z10}-LPM and Mo^{Z10}-LPM purified from donor
1073 mice 8 weeks post 10µg zymosan into naïve recipient mice followed by intraperitoneal treatment with
1074 5µg LPS.


1075 (j)Proportion of donor CD45.2⁺ F4/80^{Hi} RM^{Z10}-LPM(n=7) and Mo^{Z10}-LPM (n=6) 8 hours post LPS
1076 that are TNFα positive. *p<0.05 determined by student's t test.

1077

1078 For all experiments, data are presented as mean ± standard deviation with each symbol representing
1079 an individual animal. Naïve animals were age matched to zymosan treated (15-18Wk) animals except
1080 for (c,g) where naïve animals were 10-12Wk at the time of analysis. All data were pooled from 2
1081 independent experiments.

1082

Figure 4



1083
1084

1085

1086 **Figure 4. Ontogeny does not dictate monocyte phenotype after severe peritonitis in females and**
1087 **leads to impaired B1 cell expansion.**

1088 **(a)** Non host chimerism of Tim4⁺ macrophages 17d after indicated zymosan dose in tissue-protected
1089 BM chimeric mice. Zymosan treatment 8 (circle) or 26 (square) wks after irradiation. **p<0.01
1090 determined by one-way ANOVA and Tukey's multiple comparisons test

1091 **(b)** Engraftment efficiency of transferred RMac^{Z10} (n=6), IMac^{Z10} (n=5), and IMac^{Z1000} (n=6), after
1092 transfer into the mirroring recipients. **p<0.01 determined by one-way ANOVA and Tukey's
1093 multiple comparisons test

- 1094 (c) Representative expression of F4/80 and MHCII of indicated donor populations 8wks post after
1095 transfer. Bottom, representative expression of host myeloid cells post zymosan or post depletion.
- 1096 (d) Mean fluorescence intensity of GATA6 of donor RMac^{Z10}, IMac^{Z10} and IMac^{Z10} after transfer into
1097 native recipients (n=3,2,3). **p<0.01 determined by one-way ANOVA and Tukey's multiple
1098 comparisons test
- 1099 (e) Expression of markers of interest by CD102⁺ or F4/80⁺ donor RMac^{Z10} (blue), IMac^{Z10} (orange)
1100 and IMac^{Z1000} (purple) 8wks after transfer into mirroring (left; n=6,5,6) recipients. *p<0.05 **p<0.01
1101 ***p<0.001 determined by one way ANOVA and Dunnet's multiple comparisons test for each marker
1102 individually, followed by Bonferroni adjustment.
- 1103 (f) Principal component analysis based on all markers assessed in (e) on indicated cell populations.
- 1104 (g) Experimental scheme for adoptive transfer of F4/80^{Hi} MHCII^{Lo} naïve resident macrophages
1105 (RMac)
- 1106 (h) Representative expression of F4/80 (top), Tim4 (bottom) and MHCII on transferred RMac and
1107 host myeloid cells 8d post transfer.
- 1108 (i) Proportion of RMac that express MHCII and F4/80 (set to 100% pre-transfer as cells were sorted
1109 on this marker) before transfer and 8d post-transfer (n=5; left) and absolute number of host Tim4⁺ or
1110 Tim4⁻ macrophages 8d post-transfer (n=5). *p<0.05 ****p<0.0001 determined by student's t test.
- 1111 (j) Absolute number of host macrophages that express CXCL13 8wks after 10µg of zymosan (n=11)
1112 or 1000µg zymosan (n=6). **p<0.01 determined by student's t test.
- 1113 (k) Absolute number of peritoneal B1 cells in naïve female mice at indicated age in weeks
1114 (n=5/timepoint). ***p<0.001 determined by one-way ANOVA and post hoc Tukey test
- 1115 (l) Absolute number of peritoneal B1 cells at indicated timepoints in naïve (black circle; n= 5,6,10),
1116 post 10µg zymosan (grey square; n=6,11,20) and post 1000µg zymosan (white square; n=3,3,4)
1117 *p<0.05, ***p<0.001, ****p<0.0001 determined by two-way ANOVA and post hoc Tukey test.
- 1118 (m) Detection of serum anti phosphorylcholine specific IgM and IgG using enzyme linked
1119 immunosorbent assay from naïve (n=6), 8wks post low dose zymosan (n=16) and 8wks post high
1120 dose zymosan (n=2). *p<0.05 ***p<0.001 determined by one way ANOVA and Dunnet's multiple
1121 comparisons test

1122


1123 For all experiments, data are presented as mean ± standard deviation with each symbol representing
1124 an individual animal. All data were pooled from at least 2 independent experiments except high dose
1125 presented in (l,m) which is from a single experiment. Where presented, host cells represented by
1126 squares or circles are from animals given RMac^{Z10} or IMac^{Z10} respectively.

1127

1128

1129

Supplementary Figure 1



1130
1131

1132

1133 **Supplementary Figure 1. A toolbox to investigate inflammatory macrophage fate**

1134 **(a)** Dye labelling efficiency of F4/80^{HI} MHCII^{LO} resident macrophages (grey) and F4/80^{LO} MHCII^{HI}
1135 CD226⁺ small peritoneal macrophages (green) or CD226⁻ DCs or immature macrophages (purple)
1136 24hrs after intraperitoneal administration of PKH26-PCL (n=3). **p<0.01 by determined one-way
1137 ANOVA with Tukey's multiple comparisons test.

1138 **(b)** Experimental scheme for the adoptive transfer of unlabelled CD45.1/2⁺ peritoneal exudate cells
1139 (PEC) into the peritoneal cavity of CD45.2⁺ mice injected with PKH26-PCL intraperitoneally
1140 24hrs prior.

1141 **(c)** Representative PKH26-PCL labelling and quantification of donor F4/80^{hi} macrophages prior to
1142 transfer (top) and 2hrs post transfer (red; n=3) compared to recipient F4/80^{hi} macrophages (black).
1143 ****p<0.0001 determined by one-way ANOVA with Tukey's multiple comparisons test.

1144 **(d)** Non-host chimerism of F4/80^{HI} PKH26-PCL^{HI} RMac in the naïve peritoneal cavity (white bar)
1145 and F4/80^{HI} PKH26-PCL^{HI} RMac^{Z10} and PKH26-PCL^{LO} F4/80^{INT} IMac^{Z10} 3d post 10µg zymosan
1146 (hatched bars). Dye injection given 8wks after irradiation and zymosan injection given 24hrs
1147 thereafter.

1148 **(e)** Expression of F4/80, MHCII and Tim4 by RMac(black), RMac^{Z10}(blue) and IMac^{Z10} 3 days post
1149 10µg zymosan. ***p<0.001 ****p<0.0001 determined one-way ANOVA with Dunnet's multiple

1150 comparisons test for each marker individually, followed by Bonferroni adjustment.

1151

1152 For all experiments, data are presented as mean \pm standard deviation with each symbol representing

1153 an individual animal. All data were pooled from at least 2 independent experiments, except for **(a,c,f)**


1154 which are from single experiments.

1155

1156

1157

Supplementary figure 2



1158

1159

1160

1161 **Supplementary Figure 2. Competition mediates inflammatory macrophage survival and**
 1162 **phenotype during early resolution**

1163 (a) Representative expression of GATA6 by indicated donor populations 8d post transfer into
 1164 inflamed recipients (top) and by host macrophage subsets identified using F4/80 and MHCII (bottom).

1165 (b) Proportion of donor RMac^{Z10} (n=4), IMac^{Z10} (n=5) that were GATA6⁺ and MFI of GATA6
 1166 expression 8d after transfer into inflamed recipients. ****p<0.0001 determined by student's t test.

1167 (c) Proportion of host macrophage subsets that are GATA6⁺ 11d post zymosan (8d post cell transfer;
 1168 n=9) ****p<0.0001 determined by one-way ANOVA with Tukey's multiple comparisons test.

1169 (d) Proportion of donor RMac^{Z10} (n=5) and IMac^{Z10} (n=5) that were GATA6⁺ and MFI of GATA6
 1170 expression 8d after transfer into naive recipients. ****p<0.0001 determined by student's t test.

1171 (e) Representative dot-plots gated on CD11b⁺ cells and absolute number of F4/80^{Hi} resident
 1172 macrophages (black) 24hrs after intraperitoneal injection of PBS (n=3) or clodronate liposomes (n=3)
 1173 and 7d post clodronate liposome injection (n=4). ****p<0.0001 determined by one-way ANOVA and
 1174 Dunnet's multiple comparisons test.

1175 (f) Proportion of donor RMac^{Z10} (n=6) and IMac^{Z10} (n=5) that were GATA6⁺ and MFI of GATA6

1176 expression 8d after transfer into clodronate depleted recipients. * $p < 0.05$ determined by student's t
1177 test.

1178 **(g)** Proportion of donor RMac^{Z10} and IMac^{Z10} that are CD102⁺ and Tim4⁺ 8d after transfer into
1179 mirroring native (n= 7, 8), naïve (n=7) or clodronate depleted recipients (n= 8,6). **** $p < 0.0001$
1180 determined by one-way ANOVA and Sidak's multiple comparisons test.

1181


1182 For all experiments, data are presented as mean \pm standard deviation with each symbol representing
1183 an individual animal. All data were pooled from at least 2 independent experiments, except for **(e)** is
1184 from a single experiment.

1185

1186

1187

Supplementary Figure 3



1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200

Supplementary Figure 3. Colonizing inflammatory macrophages are long lived but retain cell intrinsic and environment dependent transcriptional and phenotypic differences

(a) Proportion of donor CD45.2⁺ F4/80^{Hi} RMac^{Z10} and host CD45.1/2⁺ F4/80^{Hi} macrophages that are PKH26-PCL⁺ 8wks post transfer (n=8).

(b) pooled engraftment efficiency of RMac^{Z10} and IMac^{Z10} 8wks post transfer into native recipients. Includes data presented in Figure 2b and Figure 4b. Each symbol refers to an experimental run.


*p < 0.05 determined by student's t test.

(c) Fraction of donor RMac, RMac^{Z10} and IMac^{Z10} that are F4/80^{Hi} and the proportion of which are CD102^{Hi} after transfer into native (left; n= 12,11,11) and depleted recipients (right; n = 10,8,8).

(d) Normalized F4/80 MFI on donor RMac(black), RMac^{Z10} (blue) and IMac^{Z10} (orange) after transfer into native (left; n=12,11,11) or depleted (right; n=10,10,8) recipients. F4/80 MFI is normalized to mean F4/80 MFI of RMac. *p < 0.05 determined by student's t test

- 1201 **(e)** Volcano plot of gene expression of IMac^{Z10} relative to RMac^{Z10} 8wks post transfer into native
1202 recipients.
- 1203 **(f)** Heatmap highlighting the subset of peritoneal macrophage identity genes included in the
1204 Nanostring panel and their expression by donor RMac, RMac^{Z10} and IMac^{Z10} 8wks post transfer into
1205 native recipients.
- 1206 **(g)** GSEA of mRNA in RMac^{Z10} and IMac^{Z10} against genes up and downregulated genes in GATA6^{KO}
1207 LPM (left). In the middle, proportion of differentially expressed genes between IMac^{Z10} and RMac^{Z10}
1208 that are regulated by GATA6 (left) and their transcriptional directionality. On the right, transcriptional
1209 directionality of the same genes in GATA6^{KO} LPM relative to WT.
- 1210 **(h)** Proportion of highly expressed single cell cluster genes that are regulated by GATA6 in cluster 3
1211 and 5 as described by Bain et al¹⁵ and the transcriptional directionality of these genes in GATA6^{KO}
1212 LPM relative to WT.
- 1213 **(i)** Volcano plot of gene expression of IMac^{Z10} relative to RMac^{Z10} 8wks post transfer into depleted
1214 recipients.
- 1215 **(j)** Expression of markers of interest by CD102⁺ or F4/80⁺ donor RMac (black) RMac^{Z10} (blue),
1216 IMac^{Z10} (orange) 8wks post transfer into native (n=4,3,3) and depleted recipients (n=2,3,2). Data
1217 obtained from a single experiment. *p<0.05 determined by one way Anova and Dunnet's multiple
1218 comparisons test for each marker individually, followed by Bonferroni adjustment.
- 1219 **(k)** Expression of markers of interest by CD102⁺ or F4/80⁺ donor RMac (black; n=4) RMac^{Z10} (blue;
1220 n=5), IMac^{Z10} (orange; n=5) 22wks post transfer into native recipients. **p<0.01 determined by one
1221 way Anova and Dunnet's multiple comparisons test for each marker individually, followed by
1222 Bonferroni adjustment.
- 1223
- 1224 For all experiments, data are presented as mean ± standard deviation with each symbol representing
1225 an individual animal. All data were pooled from at least 2 independent experiments, except for **(i)**
1226 which is from a single experiments.
- 1227
- 1228
- 1229

Supplementary figure 4



1230
1231

1232

1233 **Supplementary Figure 4. Monocyte derived LPM are functionally distinct from embryonically**
1234 **seeded LPM**

1235 **(a)** Representative expression of Tim4 and Sema4a by LPM from naïve mice or 8wks post zymosan
1236 injection

1237 **(b)** Proportion of host LPM with Sema4a^{Lo}Tim4⁺(R1), Sema4a^{Hi}Tim4⁺(R2), Sema4a^{Hi}Tim4⁻ (R3) or
1238 Sema4a^{Lo}Tim4⁻ (R4) phenotype 8wks post zymosan (6 naïve v 12 zymosan treated) and 22wks post
1239 zymosan 4 naïve v 10 zymosan treated) compared to naïve control. On the right, proportion of LPM
1240 with Sema4a^{Lo}Tim4⁺(R1), Sema4a^{Hi}Tim4⁺(R2), Sema4a^{Hi}Tim4⁻ (R3) or Sema4a^{Lo}Tim4⁻ (R4)

1241 phenotype 8wks post zymosan (15 naïve v 8 zymosan treated). ***p<0.001**p<0.01 determined by
1242 repeated student's t test with Holm-Sidak correction.

1243 **(c)** Proportion of Sema4a^{Lo}Tim4⁻ (R4) and Sema4a^{Hi}Tim4⁻ (R3) that are MHCII⁺ in naïve (n=15) and
1244 zymosan treated (n=7) mice. ***p<0.001****p<0.0001 determined by paired student's t test.

1245 **(d)** Fraction of naïve or post zymosan host F4/80⁺Tim4^{+/-} macrophages that are PKH26-PCL labelled
1246 8d after receiving PKH26-PCL labelled RMac(n=7). *p<0.05***p<0.0001 determined by one way
1247 ANOVA with Sidak multiple comparison test.

1248 **(e)** Absolute number of host naïve or post zymosan host Tim4⁺ macrophages 8d after receiving
1249 PKH26-PCL labelled RMac (n=7). **p<0.01 determined by student's t test.

1250 **(f)** Secreted cytokine/chemokine profile collected from cultures of RM-LPM or RM^{Z10}-LPM (n=6),
1251 sourced from naïve or 8wks post zymosan mice, 14hrs after culture with LPS (1ng/ml). Results are
1252 shown as log₂ fold change in mean pg/ml over the mean RM-LPM using a box-and-whiskers plot.

1253 **(g)** Secreted cytokine/chemokine profile collected from cultures of Mo-LPM or Mo^{Z10}-LPM (n=6),
1254 sourced from naïve or 8wks post zymosan mice, 14hrs after culture with LPS (1ng/ml). Results are
1255 shown as log₂ fold change in mean pg/ml over the mean Mo-LPM using a box-and-whiskers plot.

1256 *p<0.05determined by repeated student's t test with Holm-Sidak correction.


1257 For all experiments, data are presented as mean ± standard deviation with each symbol representing
1258 an individual animal. All data were pooled from at least 2 independent experiments.

1259

1260

1261

Supplementary Figure 5



1262

1263

1264 **Supplementary Figure 5. Ontogeny does not dictate monocyte phenotype after severe peritonitis**
 1265 **in females and leads to impaired B1 cell expansion.**

1266

1267 **(a)** Absolute number of CD11b⁺ myeloid cells and neutrophils at indicated timepoints in naïve (black
1268 circle; n= 5,6,10), post low dose zymosan (grey square; n=6,11,20) and post high dose zymosan
1269 (white square; n=3,3,4) *p<0.05, ***p<0.001, ****p<0.0001 for naïve and low dose determined by
1270 two-way ANOVA and post hoc Tukey test. For high dose determined by one-way ANOVA and post
1271 hoc Tukey test

1272 **(b)** Representative expression of F4/80, MHCII and Tim4 by at indicated timepoints in naïve, 10 or
1273 1000µg zymosan treated mice.

1274 **(c)** Non host chimerism of CD11B⁺ myeloid cells 17d after indicated zymosan dose in tissue-
1275 protected BM chimeric mice. Zymosan treatment 8 (circle) or 26 (square) wks after irradiation.
1276 **p<0.01 determined by one-way ANOVA and Tukey's multiple comparisons test

1277 **(d)** Representative expression of F4/80, Ly6C and PKH26-PCL labelling and identification of F4/80^{HI}
1278 PKH26-PCL^{HI} resident macrophages (RMac^{Z10}) and PKh26-PCL^{LO} F4/80^{INT} inflammatory
1279 macrophages3d after 10µg (IMac^{Z10}) or 1000µg (IMac^{Z1000}) zymosan.

1280 **(e)** Expression of markers of interest by CD102⁺/F4/80⁺ donor RMac^{Z10}(n=6) ,IMac^{Z10} (n=5) or
1281 IMac^{Z1000} (n=6) and their respective CD102⁺/F4/80⁺ host macrophages. *p<0.05 **p<0.01
1282 ***p<0.001 ****p<0.001 determined by repeated student's t test with Holm-Sidak correction

1283 **(f)** Absolute number of CD11b⁺ B1 cells 8wks after 10µg of zymosan (n=11) or 1000µg zymosan
1284 (n=6) with transfer or IMac or IMac¹⁰⁰⁰ at D3 respectively. *p<0.05 determined by student's t test.
1285

1286 For all experiments, data are presented as mean ± standard deviation with each symbol representing
1287 an individual animal. All data were pooled from at least 2 independent experiments except (a) where
1288 high dose datapoints where from a single experiment.
1289